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stract
Th
e
C
on
cise
G
uide
to
PH
A
R
M
A
C
O
LO
G
Y
2017/18
provides
con
cise
overview
s
of
th
e
key
properties
of
n
early
1800
h
um
an
drug
targets
w
ith
an
em
ph
asis
on
selective
ph
arm
acology
(w
h
ere
available),
plus
lin
ks
to
an
open
access
kn
ow
ledgebase
of
drug
targets
an
d
th
eir
ligan
ds
(w
w
w
.guidetoph
arm
acology.org),w
h
ich
provides
m
ore
detailed
view
s
of
target
an
d
ligan
d
properties.
A
lth
ough
th
e
C
on
cise
G
uide
represen
ts
approxim
ately
400
pages,th
e
m
aterial
presen
ted
is
substan
tially
reduced
com
pared
to
in
form
ation
an
d
lin
ks
presen
ted
on
th
e
w
ebsite.
It
provides
a
perm
an
en
t,citable,poin
t-in
-tim
e
record
th
at
w
ill
survive
database
updates.
Th
e
full
con
ten
ts
of
th
is
section
can
be
foun
d
at
h
ttp://on
lin
elibrary.w
iley.com
/doi/10.1111/bph
.13876/full.
C
atalytic
receptors
are
on
e
of
th
e
eigh
t
m
ajor
ph
arm
acologicaltargets
in
to
w
h
ich
th
e
G
uide
is
divided,w
ith
th
e
oth
ers
bein
g:G
protein
-coupled
receptors,ligan
d-gated
ion
ch
an
n
els,voltage-gated
ion
ch
an
n
els,oth
er
ion
ch
an
n
els,n
uclear
h
orm
on
e
receptors,en
zym
es
an
d
tran
sporters.Th
ese
are
presen
ted
w
ith
n
om
en
clature
guidan
ce
an
d
sum
m
ary
in
form
ation
on
th
e
best
available
ph
arm
acologicaltools,alon
gside
key
referen
ces
an
d
suggestion
s
for
furth
er
readin
g.Th
e
lan
dscape
form
at
ofth
e
C
on
cise
G
uide
is
design
ed
to
facilitate
com
parison
ofrelated
targets
from
m
aterialcon
tem
porary
to
m
id-2017,an
d
supersedes
data
presen
ted
in
th
e
2015/16
an
d
2013/14
C
on
cise
G
uides
an
d
previous
G
uides
to
R
eceptors
an
d
C
h
an
n
els.
It
is
produced
in
close
con
jun
ction
w
ith
th
e
N
om
en
clature
C
om
m
ittee
of
th
e
U
n
ion
of
Basic
an
d
C
lin
ical
Ph
arm
acology
(N
C
-IU
PH
A
R
),th
erefore,providin
g
officialIU
PH
A
R
classification
an
d
n
om
en
clature
for
h
um
an
drug
targets,w
h
ere
appropriate.
C
o
n
fl
ict
o
f
in
terest
Th
e
auth
ors
state
th
at
th
ere
are
n
o
con
flicts
of
in
terest
to
declare.
c⃝
2017
Th
e
A
uth
ors.British
Journ
alof
Ph
arm
acology
publish
ed
by
Joh
n
W
iley
&
Son
s
Ltd
on
beh
alf
of
British
Ph
arm
acologicalSociety.
Th
is
is
an
open
access
article
un
der
th
e
term
s
ofth
e
C
reative
C
om
m
on
s
A
ttribution
Licen
se,w
h
ich
perm
its
use,distribution
an
d
reproduction
in
an
y
m
edium
,provided
th
e
origin
alw
ork
is
properly
cited.
O
verview
:
C
atalytic
receptors
are
cell-surface
protein
s,
usually
dim
eric
in
n
ature,
w
h
ich
en
com
pass
ligan
d
bin
din
g
an
d
fun
c-
tion
al
dom
ain
s
in
on
e
polypeptide
ch
ain
.
Th
e
ligan
d
bin
din
g
dom
ain
is
placed
on
th
e
extracellular
surface
ofth
e
plasm
a
m
em
-
bran
e
an
d
separated
from
th
e
fun
ction
al
dom
ain
by
a
sin
gle
tran
sm
em
bran
e-span
n
in
g
dom
ain
of
20-25
h
ydroph
obic
am
in
o
acids.
Th
e
fun
ction
al
dom
ain
on
th
e
in
tracellular
face
of
th
e
plasm
a
m
em
bran
e
h
as
catalytic
activity,or
in
teracts
w
ith
particu-
laren
zym
es,givin
g
th
e
superfam
ily
ofreceptorsitsn
am
e.En
doge-
n
ous
agon
ists
ofth
e
catalytic
receptor
superfam
ily
are
peptides
or
protein
s,
th
e
bin
din
g
of
w
h
ich
m
ay
in
duce
dim
erization
of
th
e
receptor,w
h
ich
is
th
e
fun
ction
alversion
of
th
e
receptor.
A
m
on
gst
th
e
catalytic
receptors,
particular
subfam
ilies
m
ay
be
readily
iden
tified
depen
den
t
on
th
e
fun
ction
of
th
e
en
zym
atic
portion
of
th
e
receptor.
Th
e
sm
allest
group
is
th
e
particulate
guan
ylyl
cyclases
of
th
e
n
atriuretic
peptide
receptor
fam
ily.
Th
e
m
ostw
idely
recogn
ized
group
is
probably
th
e
receptortyrosin
e
ki-
n
ase
(R
TK
)
fam
ily,epitom
ized
by
th
e
n
eurotroph
in
receptor
fam
-
ily,
w
h
ere
a
crucial
in
itial
step
is
th
e
activation
of
a
sign
allin
g
cascade
by
autoph
osph
orylation
of
th
e
receptor
on
in
tracellular
tyrosin
e
residue(s)
catalyzed
by
en
zym
e
activity
in
trin
sic
to
th
e
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w
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receptor.
A
th
ird
group
is
th
e
extrin
sic
protein
tyrosin
e
kin
ase
receptors,
w
h
ere
th
e
catalytic
activity
resides
in
a
separate
pro-
tein
from
th
e
bin
din
g
site.
Exam
ples
of
th
is
group
in
clude
th
e
G
D
N
F
an
d
ErbB
receptor
fam
ilies,w
h
ere
on
e,catalytically
silen
t,
m
em
ber
of
th
e
h
eterodim
er
is
activated
upon
bin
din
g
th
e
lig-
an
d,
causin
g
th
e
secon
d
m
em
ber
of
th
e
h
eterodim
er,
lackin
g
ligan
d
bin
din
g
capacity,
to
in
itiate
sign
alin
g
th
rough
tyrosin
e
ph
osph
orylation
.
A
fourth
group,
th
e
receptor
th
reon
in
e/serin
e
kin
ase
(R
TSK
)
fam
ily,
exem
plified
by
TG
F-β
an
d
BM
P
receptors,
h
as
in
trin
sic
serin
e/th
reon
in
e
protein
kin
ase
activity
in
th
e
h
et-
erodim
eric
fun
ction
al
un
it.
A
fifth
group
is
th
e
receptor
tyrosin
e
ph
osph
atases
(R
TP),
w
h
ich
appear
to
lack
cogn
ate
ligan
ds,
but
m
ay
be
triggered
by
even
ts
such
as
cell:cellcon
tactan
d
h
ave
iden
-
tified
roles
in
th
e
skeletal,h
em
atopoietic
an
d
im
m
un
e
system
s.
A
furth
er
group
of
catalytic
receptors
for
th
e
G
uide
is
th
e
in
te-
grin
s,
w
h
ich
h
ave
roles
in
cell:cell
com
m
un
ication
,
often
associ-
ated
w
ith
sign
alin
g
in
th
e
blood.
Fam
ily
stru
ctu
re
S226
C
ytokin
e
receptor
fam
ily
S227
IL-2
receptor
fam
ily
S228
IL-3
receptor
fam
ily
S229
IL-6
receptor
fam
ily
S231
IL-12
receptor
fam
ily
S232
Prolactin
receptor
fam
ily
S232
In
terferon
receptor
fam
ily
S233
IL-10
receptor
fam
ily
S234
Im
m
un
oglobulin
-like
fam
ily
of
IL-1
receptors
S235
IL-17
receptor
fam
ily
S236
G
D
N
F
receptor
fam
ily
S237
In
tegrin
s
S241
N
atriuretic
peptide
receptor
fam
ily
S242
Pattern
recogn
ition
receptors
S242
Toll-like
receptor
fam
ily
S244
N
O
D
-like
receptor
fam
ily
–
R
IG
-I-like
receptor
fam
ily
–
R
eceptor
kin
ases
–
TK
:Tyrosin
e
kin
ase
S246
R
eceptor
tyrosin
e
kin
ases
(R
TK
s)
S246
Type
I
R
TK
s:ErbB
(epiderm
algrow
th
fac-
tor)
receptor
fam
ily
S247
Type
II
R
TK
s:In
sulin
receptor
fam
ily
S248
Type
III
R
TK
s:PD
G
FR
,C
SFR
,K
it,FLT3
receptor
fam
ily
S250
Type
IV
R
TK
s:V
EG
F
(vascular
en
doth
elial
grow
th
factor)
receptor
fam
ily
S250
Type
V
R
TK
s:FG
F
(fibroblast
grow
th
fac-
tor)
receptor
fam
ily
S251
Type
V
I
R
TK
s:PTK
7/C
C
K
4
S252
Type
V
II
R
TK
s:N
eurotroph
in
receptor/Trk
fam
ily
S253
Type
V
III
R
TK
s:R
O
R
fam
ily
S253
Type
IX
R
TK
s:M
uSK
S254
Type
X
R
TK
s:H
G
F
(h
epatocyte
grow
th
factor)
receptor
fam
ily
S255
Type
X
I
R
TK
s:TA
M
(TY
R
O
3-,A
X
L-an
d
M
ER
-TK
)
receptor
fam
ily
S255
Type
X
II
R
TK
s:TIE
fam
ily
of
an
giopoietin
receptors
S256
Type
X
III
R
TK
s:Eph
rin
receptor
fam
ily
S256
Type
X
IV
R
TK
s:R
ET
S257
Type
X
V
R
TK
s:RY
K
S258
Type
X
V
I
R
TK
s:D
D
R
(collagen
receptor)
fam
ily
S258
Type
X
V
II
R
TK
s:R
O
S
receptors
S258
Type
X
V
III
R
TK
s:LM
R
fam
ily
S259
Type
X
IX
R
TK
s:Leukocyte
tyrosin
e
kin
ase
(LTK
)
receptor
fam
ily
S260
Type
X
X
R
TK
s:STY
K
1
–
TK
L:Tyrosin
e
kin
ase-like
S260
R
eceptor
serin
e/th
reon
in
e
kin
ase
(R
STK
)
fam
-ily
S261
Type
I
receptor
serin
e/th
reon
in
e
kin
ases
S261
Type
II
receptor
serin
e/th
reon
in
e
kin
ases
S262
Type
III
receptor
serin
e/th
reon
in
e
kin
ases
S262
R
STK
fun
ction
alh
eterom
ers
S264
R
eceptor
tyrosin
e
ph
osph
atase
(R
TP)
fam
ily
S265
Tum
our
n
ecrosis
factor
(TN
F)
receptor
fam
ily
C
ytokine
receptor
fam
ily
C
atalytic
receptors→
C
ytokin
e
receptor
fam
ily
O
verview
:
C
ytokin
es
are
n
ot
a
clearly
defin
ed
group
of
agen
ts,
oth
er
th
an
h
avin
g
an
im
pact
on
im
m
un
e
sign
allin
g
path
w
ays,al-
th
ough
m
an
y
cytokin
es
h
ave
effects
on
oth
er
system
s,such
as
in
developm
en
t.
A
feature
of
som
e
cytokin
es,w
h
ich
allow
s
th
em
to
be
distin
guish
ed
from
h
orm
on
es,
is
th
at
th
ey
m
ay
be
produced
by
ın
on
-secretory 
cells,
for
exam
ple,
en
doth
elial
cells.
W
ith
in
th
e
cytokin
e
receptor
fam
ily,
som
e
subfam
ilies
m
ay
be
iden
ti-
fied,
w
h
ich
are
described
elsew
h
ere
in
th
e
G
uide
to
PH
A
R
M
A
-
C
O
LO
G
Y,receptors
for
th
e
TN
F
fam
ily,th
e
TG
F-β
fam
ily
an
d
th
e
ch
em
okin
es.
W
ith
in
th
is
group
of
records
are
described
Type
I
cytokin
e
receptors,
typified
by
in
terleukin
receptors,
an
d
Type
II
cytokin
e
receptors,exem
plified
by
in
terferon
receptors.
Th
ese
re-
ceptors
possess
a
con
served
extracellular
region
,
kn
ow
n
as
th
e
cytokin
e
receptor
h
om
ology
dom
ain
(C
H
D
),
alon
g
w
ith
a
ran
ge
ofoth
er
structuralm
odules,in
cludin
g
extracellular
im
m
un
oglob-
ulin
(Ig)-like
an
d
fibron
ectin
type
III
(FBN
III)-like
dom
ain
s,
a
tran
sm
em
bran
e
dom
ain
,
an
d
in
tracellular
h
om
ology
dom
ain
s.
A
n
un
usualfeature
of
th
is
group
of
agen
ts
is
th
e
existen
ce
of
sol-
uble
an
d
decoy
receptors.
Th
ese
bin
d
cytokin
es
w
ith
out
allow
in
g
sign
allin
g
to
occur.A
furth
erattribute
isth
e
production
ofen
doge-
n
ousan
tagon
istm
olecules,w
h
ich
bin
d
to
th
e
receptorsselectively
an
d
preven
t
sign
allin
g.A
com
m
on
ality
ofth
ese
fam
ilies
ofrecep-
torsisth
e
ligan
d-in
duced
h
om
o-orh
etero-oligom
erisation
,w
h
ich
resultsin
th
e
recruitm
en
tofin
tracellularprotein
partn
ersto
evoke
cellularrespon
ses,particularly
in
in
flam
m
atory
orh
aem
atopoietic
sign
allin
g.
A
lth
ough
n
ot
an
exclusive
sign
allin
g
path
w
ay,a
com
-
m
on
feature
of
th
e
m
ajority
of
cytokin
e
receptors
is
activation
of
th
e
JA
K
/STA
T
path
w
ay.
Th
is
cascade
is
based
aroun
d
th
e
protein
tyrosin
e
kin
ase
activity
ofth
e
Jan
uskin
ases(JA
K
),w
h
ich
ph
osph
o-
rylate
th
e
receptor
an
d
th
ereby
facilitate
th
e
recruitm
en
t
ofsign
al
Searchable
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tran
sducers
an
d
activators
of
tran
scription
(STA
Ts).
Th
e
activated
h
om
o-
or
h
eterodim
eric
STA
Ts
fun
ction
prin
cipally
as
tran
scrip-
tion
factors
in
th
e
n
ucleus.
T
yp
e
I
cyto
k
in
e
recep
to
rs
are
ch
aracterized
by
tw
o
pairs
of
con
served
cystein
es
lin
ked
via
disulfide
bon
ds
an
d
a
C
-term
in
al
W
SX
W
S
m
otif
w
ith
in
th
eir
C
H
D
.Type
I
receptors
are
com
m
on
ly
classified
in
to
five
groups,
based
on
sequen
ce
an
d
structual
h
o-
m
ology
of
th
e
receptor
an
d
its
cytokin
e
ligan
d,
w
h
ich
is
poten
-
tially
m
ore
reflective
ofevolution
ary
relation
sh
ips
th
an
an
earlier
sch
em
e
based
on
th
e
use
of
com
m
on
sign
al
tran
sducin
g
ch
ain
s
w
ith
in
a
receptor
com
plex.
T
yp
e
II
cyto
k
in
e
recep
to
rs
also
h
ave
tw
o
pairs
of
con
served
cystein
es
but
w
ith
a
differen
t
arran
gem
en
t
to
Type
Ian
d
also
lack
th
e
W
SX
W
S
m
otif.
IL-2
receptor
fam
ily
C
atalytic
receptors→
C
ytokin
e
receptor
fam
ily→
IL-2
receptor
fam
ily
O
verview
:Th
e
IL-2
receptor
fam
ily
con
sists
ofon
e
or
m
ore
ligan
d-selective
subun
its,an
d
a
com
m
on
γ
ch
ain
(γc):IL2RG
,P31785),th
ough
IL-4
an
d
IL-7
receptors
can
form
com
plexes
w
ith
oth
er
receptor
ch
ain
s.R
eceptors
ofth
is
fam
ily
associate
w
ith
Jak1
an
d
Jak3,prim
arily
activatin
g
Stat5,alth
ough
certain
fam
ily
m
em
bers
can
also
activate
Stat1,Stat3,or
Stat6.R
o264550
h
as
been
described
as
a
selective
IL-2
receptor
an
tagon
ist,w
h
ich
bin
ds
to
IL-2
[204].
N
om
enclature
Interleukin-2
receptor
Interleukin-4
receptor
type
I
Interleukin-4
receptor
type
II
Interleukin-7
receptor
Interleukin-9
receptor
Subunits
Interleukin-2
receptor
subunitβ
(Ligand-binding
subunit),
Interleukin-2
receptor
subunitγ
(O
ther
subunit),
Interleukin-2
receptor
subunitα
(Ligand-binding
subunit)
Interleukin-4
receptor
subunitα
(Ligand-binding
subunit),
Interleukin-2
receptor
subunitγ
(O
ther
subunit)
Interleukin-13
receptor
subunitα
1
(O
ther
subunit),
Interleukin-4
receptor
subunitα
(Ligand-binding
subunit)
Interleukin-2
receptor
subunitγ
(O
ther
subunit),
Interleukin-7
receptor
subunitα
(Ligand-binding
subunit)
Interleukin-2
receptor
subunitγ
(O
ther
subunit),
Interleukin
9
receptor
(Ligand-binding
subunit)
Endogenous
agonists
IL-2
(IL2,P60568)
IL-4
(IL4,P05112)
IL-13
(IL13,P35225),IL-4
(IL4,
P05112)
IL-7
(IL7,P13232)
IL-9
(IL9,P15248)
Endogenous
antagonists
IL-1
receptor
antagonist
(IL1RN
,
P18510)
–
–
–
–
Selective
antagonists
AF12198
[1]
–
–
–
–
Searchable
database:http://w
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N
om
enclature
Interleukin
13
receptor,α
2
Interleukin-15
receptor
Interleukin-21
receptor
Thym
ic
strom
allym
phopoietin
receptor
H
G
N
C
,U
niProt
IL13RA2,Q
14627
–
–
–
Subunits
–
Interleukin-2
receptor
subunitβ
(Ligand-binding
subunit),
Interleukin-15
receptor
subunitα
(Ligand-binding
subunit),
Interleukin-2
receptor
subunitγ
(O
ther
subunit)
Interleukin-2
receptor
subunitγ
(O
ther
subunit),Interleukin
21
receptor
(Ligand-binding
subunit)
C
ytokine
receptor-like
factor
2
(O
ther
subunit),Interleukin-7
receptor
subunitα
(Ligand-binding
subunit)
Endogenous
agonists
–
IL-15
(IL15,P40933)
IL-21
(IL21,Q
9H
BE4)
thym
ic
strom
allym
phopoietin
(TSLP,
Q
969D
9)
C
om
m
ents
D
ecoy
receptor
that
binds
IL-13
(IL13,
P35225)
as
a
m
onom
er.
–
–
–
Subunits
N
om
enclature
Interleukin-2
receptor
subunitα
Interleukin-2
receptor
subunitβ
Interleukin-2
receptor
subunitγ
Interleukin-4
receptor
subunitα
Interleukin-7
receptor
subunitα
H
G
N
C
,U
niProt
IL2RA,P01589
IL2RB,P14784
IL2RG
,P31785
IL4R,P24394
IL7R,P16871
Antibodies
daclizum
ab
(pK
d
>
8)
[176],
basilixim
ab
–
–
dupilum
ab
(pIC
50
11.1)
[140]
–
N
om
enclature
Interleukin
9
receptor
Interleukin-13
receptor
subunitα
1
Interleukin-15
receptor
subunitα
Interleukin
21
receptor
C
ytokine
receptor-like
factor
2
H
G
N
C
,U
niProt
IL9R,Q
01113
IL13RA1,P78552
IL15RA,Q
13261
IL21R,Q
9H
BE5
CRLF2,Q
9H
C
73
Searchable
database:http://w
w
w.guidetopharm
acology.org/index.jsp
IL-2
receptor
fam
ily
S228
FullC
ontents
ofC
onciseG
uide:http://onlinelibrary.w
iley.com
/doi/10.1111/bph.13876/full
S.P.H.Alexanderetal.The
Concise
Guide
to
PHARM
ACOLOGY
2017/18:Catalytic
receptors.British
JournalofPharm
acology
(2017)174,S225–S271
IL-3
receptor
fam
ily
C
atalytic
receptors→
C
ytokin
e
receptor
fam
ily→
IL-3
receptor
fam
ily
O
verview
:
Th
e
IL-3
receptor
fam
ily
sign
al
th
rough
a
receptor
com
plex
com
prisin
g
of
a
ligan
d-specific
α
subun
it
an
d
a
com
m
on
β
ch
ain
(C
SF2RB,
P32927),
w
h
ich
is
associated
w
ith
Jak2
an
d
sign
als
prim
arily
th
rough
Stat5.
N
om
enclature
Interleukin-3
receptor
Interleukin-5
receptor
G
ranulocyte
m
acrophage
colony-stim
ulating
factor
receptor
Subunits
Interleukin
3
receptor,α
subunit
(Ligand-binding
subunit),C
ytokine
receptor
com
m
on
β
subunit
(O
ther
subunit)
Interleukin
5
receptor,α
subunit
(Ligand-binding
subunit),C
ytokine
receptor
com
m
on
β
subunit
(O
ther
subunit)
G
M
-C
SF
receptor,α
subunit
(Ligand-binding
subunit),
C
ytokine
receptor
com
m
on
β
subunit
(O
ther
subunit)
Endogenous
agonists
IL-3
(IL3,P08700)
IL-5
(IL5,P05113)
G
-C
SF
(CSF3,P09919),G
M
-C
SF
(CSF2,P04141)
Selective
antagonists
–
YM
90709
[134]
–
Subunits
N
om
enclature
Interleukin
3
receptor,α
subunit
Interleukin
5
receptor,α
subunit
G
M
-C
SF
receptor,α
subunit
C
ytokine
receptor
com
m
on
β
subunit
H
G
N
C
,U
niProt
IL3RA,P26951
IL5RA,Q
01344
CSF2RA,P15509
CSF2RB,P32927
Endogenous
agonists
IL-3
(IL3,P08700)
IL-5
(IL5,P05113)
G
M
-C
SF
(CSF2,P04141)
–
Antibodies
–
benralizum
ab
(pK
d
8.7)
[109]
m
avrilim
um
ab
(pIC
50
9.9)
[32]
–
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IL-6
receptor
fam
ily
C
atalytic
receptors→
C
ytokin
e
receptor
fam
ily→
IL-6
receptor
fam
ily
O
verview
:Th
e
IL-6
receptor
fam
ily
sign
alth
rough
a
tern
ary
receptor
com
plex
con
sistin
g
ofth
e
cogn
ate
receptor
an
d
eith
er
th
e
IL-6
sign
altran
sducer
gp130
(IL6ST
,P40189)or
th
e
on
costatin
M
-specific
receptor,
β
subun
it
(O
SM
R,
Q
99650),
w
h
ich
th
en
activates
th
e
JA
K
/STA
T,
R
as/R
af/M
A
PK
an
d
PI
3-kin
ase/PK
B
sign
allin
g
m
odules.
U
n
usually
am
on
gst
th
e
cytokin
e
receptors,
th
e
C
N
TF
receptor
is
a
glyceroph
osph
atidylin
ositol-lin
ked
protein
.
N
om
enclature
Interleukin-6
receptor
Interleukin-11
receptor
Interleukin-27
receptor
Interleukin-31
receptor
C
iliary
neutrophic
factor
receptor
Leukem
ia
inhibitory
factor
receptor
O
ncostatin-M
receptor
Subunits
Interleukin-6
receptor,
α
subunit
(Ligand-binding
subunit),
Interleukin-6
receptor,
β
subunit
(O
ther
subunit)
Interleukin-11
receptor,α
subunit
(Ligand-binding
subunit),
Interleukin-6
receptor,β
subunit
(O
ther
subunit)
Interleukin-6
receptor,β
subunit
(O
ther
subunit),
Interleukin
27
receptor,alpha
(Ligand-binding
subunit)
Interleukin-31
receptor,α
subunit
(Ligand-binding
subunit),
O
ncostatin
M
-
specific
receptor,
β
subunit
(O
ther
subunit)
Leukem
ia
inhibitory
factor
receptor
(O
ther
subunit),
Interleukin-6
receptor,
β
subunit,
C
iliary
neurotrophic
factor
receptorα
subunit
(Ligand-binding
subunit)
Leukem
ia
inhibitory
factor
receptor
(Ligand-binding
subunit),
Interleukin-6
receptor,β
subunit
(O
ther
subunit)
Interleukin-6
receptor,β
subunit
(O
ther
subunit),
O
ncostatin
M
-specific
receptor,β
subunit
(Ligand-binding
subunit)
Endogenous
agonists
IL-6
(IL6,P05231)
[157]
IL-11
(IL11,P20809)
IL-27
(EBI3
IL27,
Q
14213
Q
8N
EV9)
IL-31
(IL31,Q
6EBC
2)
C
RC
F1/C
LC
F1
heterodim
er
(CLCF1
CRLF1,O
75462
Q
9U
BD
9),
ciliary
neurotrophic
factor
(
CN
TF,P26441)
LIF
(LIF,P15018),
cardiotrophin-1
(CTF1,Q
16619),
oncostatin
M
(O
SM
,
P13725)
oncostatin
M
(O
SM
,
P13725)
Agonists
–
oprelvekin
[10,195]
–
–
–
–
–
Antibodies
vobarilizum
ab
(pK
d
12.7)
[185],sapelizum
ab
(pK
d
8.9)
[92],tocilizum
ab
(pK
d
8.6)
–
–
–
–
–
–
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Subunits
N
om
enclature
Interleukin-6
receptor,α
subunit
Interleukin-6
receptor,β
subunit
System
atic
nom
enclature
interleukin
6
receptor
interleukin
6
signaltransducer
H
G
N
C
,U
niProt
IL6R,P08887
IL6ST,P40189
C
om
m
on
abreviation
IL6R
IL6ST
Endogenous
agonists
IL-6
(IL6,P05231)
[157]
–
Antibodies
sarilum
ab
(Binding)
(pK
d
10.6–11.1)
[198]
–
N
om
enclature
Interleukin-11
receptor,α
subunit
Interleukin
27
receptor,alpha
Interleukin-31
receptor,α
subunit
C
iliary
neurotrophic
factor
receptorα
subunit
Leptin
receptor
Leukem
ia
inhibitory
factor
receptor
O
ncostatin
M
-specific
receptor,β
subunit
H
G
N
C
,U
niProt
IL11RA,Q
14626
IL27RA,Q
6U
W
B1
IL31RA,Q
8N
I17
CN
TFR,P26992
LEPR,P48357
LIFR,P42702
O
SM
R,Q
99650
Endogenous
agonists
–
–
–
–
leptin
(LEP,P41159)
[187]–
M
ouse
–
–
Fu
rth
er
read
in
g
o
n
IL
-6
recep
to
r
fam
ily
H
o,LJetal.(2015)Biologicaleffects
ofin
terleukin
-6:C
lin
icalapplication
s
in
autoim
m
un
e
diseases
an
d
can
cers.Biochem
Pharm
acol97
:16-26
[PM
ID
:26080005]
R
oth
aug,M
etal.(2016)
Th
e
role
of
in
terleukin
-6
sign
alin
g
in
n
ervous
tissue.
Biochim
Biophys
A
cta
1863
:1218-27
[PM
ID
:27016501]
IL-12
receptor
fam
ily
C
atalytic
receptors→
C
ytokin
e
receptor
fam
ily→
IL-12
receptor
fam
ily
O
verview
:IL-12
receptors
are
a
subfam
ily
ofth
e
IL-6
receptor
fam
ily.IL12R
B1
is
sh
ared
betw
een
receptors
for
IL-12
an
d
IL-23;th
e
fun
ction
alagon
ist
at
IL-12
receptors
is
a
h
eterodim
er
ofIL-12A
/IL-12B,
w
h
ile
th
at
for
IL-23
receptors
is
a
h
eterodim
er
of
IL-12B/IL-23A
.
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N
om
enclature
Interleukin-12
receptor
Interleukin-23
receptor
Interleukin-12
receptor,β1
subunit
Interleukin-12
receptor,β2
subunit
Interleukin
23
receptor
H
G
N
C
,U
niProt
–
–
IL12RB1,P42701
IL12RB2,Q
99665
IL23R,Q
5VW
K5
Subunits
Interleukin-12
receptor,β2
subunit
(O
ther
subunit),
Interleukin-12
receptor,β1
subunit
(Ligand-binding
subunit)
Interleukin
23
receptor
(Ligand-binding
subunit),
Interleukin-12
receptor,β1
subunit
(Ligand-binding
subunit)
–
–
–
Endogenous
agonists
IL-12
(IL12A
IL12B,P29459
P29460)
IL-23
(IL12B
IL23A,P29460)
–
–
–
Prolactin
receptor
fam
ily
C
atalytic
receptors→
C
ytokin
e
receptor
fam
ily→
Prolactin
receptor
fam
ily
O
verview
:Prolactin
fam
ily
receptors
form
h
om
odim
ers
in
th
e
presen
ce
of
th
eir
respective
ligan
ds,associate
exclusively
w
ith
Jak2
an
d
sign
alvia
Stat5.
N
om
enclature
Eythropoietin
receptor
G
ranulocyte
colony-stim
ulating
factor
receptor
G
row
th
horm
one
receptor
Prolactin
receptor
Throm
bopoietin
receptor
H
G
N
C
,U
niProt
EPO
R,P19235
CSF3R,Q
99062
G
H
R,P10912
PRLR,P16471
M
PL,P40238
Endogenous
agonists
erythropoietin
(EPO
,
P01588)
[44]
G
-C
SF
(CSF3,P09919)
grow
th
horm
one
1
(G
H
1,
P01241),grow
th
horm
one
2
(G
H
2,P01242)
prolactin
(PRL,P01236)
[46]–
M
ouse,choriom
am
m
otropin
(CSH
1
CSH
2,P01243),
chorionic
som
atom
am
m
otropin
horm
one-like
1
(CSH
L1,
Q
14406)
throm
bopoietin
(TH
PO
,P40225)
Agonists
peginesatide
[44]
pegfilgrastim
–
–
rom
iplostim
Selective
agonists
–
–
–
–
eltrom
bopag
[119]
Antagonists
–
–
pegvisom
ant
[179]
–
–
Fu
rth
er
read
in
g
o
n
P
ro
lactin
recep
to
r
fam
ily
C
abrera-R
eyes,
EA
et
al.
(2017)
Prolactin
fun
ction
an
d
putative
expression
in
th
e
brain
.
Endocrine
[PM
ID
:28634745]
G
offin
,V.(2017)
Prolactin
receptor
targetin
g
in
breast
an
d
prostate
can
cers:
N
ew
in
sigh
ts
in
to
an
old
ch
allen
ge.Pharm
acolT
her
[PM
ID
:28549597]
Searchable
database:http://w
w
w.guidetopharm
acology.org/index.jsp
Prolactin
receptor
fam
ily
S232
FullC
ontents
ofC
onciseG
uide:http://onlinelibrary.w
iley.com
/doi/10.1111/bph.13876/full
S.P.H.Alexanderetal.The
Concise
Guide
to
PHARM
ACOLOGY
2017/18:Catalytic
receptors.British
JournalofPharm
acology
(2017)174,S225–S271
Interferon
receptor
fam
ily
C
atalytic
receptors→
C
ytokin
e
receptor
fam
ily→
In
terferon
receptor
fam
ily
O
verview
:
Th
e
in
terferon
receptor
fam
ily
in
cludes
receptors
for
type
I
(α
,β
κ
an
d
ω
)
an
d
type
II
(γ)
in
terferon
s.
Th
ere
are
at
least
13
differen
t
gen
es
en
codin
g
IFN
-α
subun
its
in
a
cluster
on
h
u-
m
an
ch
rom
osom
e
9p22:α
1
(IFN
A
1,P01562),α
2
(IFN
A
2,P01563),
α
4
(IFN
A
4,P05014),α
5
(IFN
A
5,P01569),α
6
(IFN
A
6,P05013),α
7
(IFN
A
7,P01567),α
8
(IFN
A
8,P32881),α
10
(IFN
A
10,P01566),α
13
(IFN
A
13,P01562),α
14
(IFN
A
14,P01570),α
16
(IFN
A
16,P05015),
α
17
(IFN
A
17,P01571)
an
d
α
21
(IFN
A
21,P01568).
N
om
enclature
Interferon-α
/β
receptor
Interferon-γ
receptor
Subunits
Interferon
α
/β
receptor
2
(O
ther
subunit),interferon
α
/β
receptor
1
(Ligand-binding
subunit)
Interferon
γ
receptor
2
(O
ther
subunit),Interferon
γ
receptor
1
(Ligand-binding
subunit)
Endogenous
agonists
IFN
-α
1/13
(IFN
A1
IFN
A13,P01562),IFN
-α
10
(IFN
A10,P01566),IFN
-α
14
(IFN
A14,
P01570),IFN
-α
16
(IFN
A16,P05015),IFN
-α
17
(IFN
A17,P01571),IFN
-α
2
(IFN
A2,
P01563),IFN
-α
21
(IFN
A21,P01568),IFN
-α
4
(IFN
A4,P05014),IFN
-α
5
(IFN
A5,
P001569),IFN
-α
6
(IFN
A6,P05013),IFN
-α
7
(IFN
A7,P01567),IFN
-α
8
(IFN
A8,
P32881),IFN
-β
(IFN
B1,P01574),IFN
-κ
(IFN
K,Q
9P0W
0),IFN
-ω
(IFN
W
1,P05000)
IFN
-γ
(IFN
G
,P01579)
Selective
agonists
peginterferon
alfa-2b
[191]
–
Subunits
N
om
enclature
interferon
α
/β
receptor
1
Interferon
α
/β
receptor
2
Interferon
γ
receptor
1
Interferon
γ
receptor
2
H
G
N
C
,U
niProt
IFN
AR1,P17181
IFN
AR2,P48551
IFN
G
R1,P15260
IFN
G
R2,P38484
Selective
agonists
peginterferon
alfa-2b
[191]
–
–
–
Antibodies
anifrolum
ab
(pK
d
>
10)
[24]
–
–
–
Fu
rth
er
read
in
g
o
n
In
terfero
n
recep
to
r
fam
ily
K
oten
ko,SV
etal.(2017)C
on
tribution
oftype
IIIin
terferon
s
to
an
tiviralim
m
un
ity:location
,loca-
tion
,location
.JBiolC
hem
292
:7295-7303
[PM
ID
:28289095]
N
g,C
T,et
al.
(2016)
A
lph
a
an
d
Beta
Type
1
In
terferon
Sign
alin
g:
Passage
for
D
iverse
Biologic
O
ut-
com
es.C
ell164
:349-52
[PM
ID
:26824652]
Sch
reiber,G
.(2017)Th
e
m
olecular
basis
fordifferen
tialtype
Iin
terferon
sign
alin
g.JBiolC
hem
292
:
7285-7294
[PM
ID
:28289098]
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IL-10
receptor
fam
ily
C
atalytic
receptors→
C
ytokin
e
receptor
fam
ily→
IL-10
receptor
fam
ily
O
verview
:
Th
e
IL-10
fam
ily
of
receptors
are
h
eterodim
eric
com
bin
ation
s
of
fam
ily
m
em
bers:
IL10R
A
/IL10R
B
respon
ds
to
IL-10;
IL20R
A
/IL20R
B
respon
ds
to
IL-19,
IL-20
an
d
IL-24;
IL22R
A
1/IL20R
B
respon
ds
to
IL-20
an
d
IL-24;IL22R
A
1/IL10R
B
respon
ds
to
IL-22;IFN
LR
1(previouly
kn
ow
n
as
IL28R
A
)/IL10R
B
respon
ds
to
IFN
-λ
1,-λ
2
an
d
-λ
3
(previouly
kn
ow
n
as
IL-29,IL-28A
an
d
IL-28B
respectively).
N
om
enclature
Interleukin-10
receptor
Interleukin-20
receptor
Interleukin-22α
1/20β
heterom
er
Interleukin-22α
1/10β
heterom
er
Interleukin-22
receptorα
2
Interferon-λ
receptor
1
H
G
N
C
,U
niProt
–
–
–
–
IL22RA2,Q
969J5
–
Subunits
Interleukin
10
receptor,
α
subunit
(Ligand-binding
subunit),
Interleukin
10
receptor,
β
subunit
(O
ther
subunit)
Interleukin
20
receptor,
β
subunit
(O
ther
subunit),
Interleukin
20
receptor,
α
subunit
(Ligand-binding
subunit)
Interleukin
22
receptor,
α
1
subunit
(Ligand-binding
subunit),
Interleukin
20
receptor,
β
subunit
(Ligand-binding
subunit)
Interleukin
22
receptor,
α
1
subunit
(Ligand-binding
subunit),
Interleukin
10
receptor,
β
subunit
(Ligand-binding
subunit)
–
Interferon-λ
receptor
subunit
1
(Ligand-binding
subunit),
Interleukin
10
receptor,
β
subunit
(O
ther
subunit)
Endogenous
agonists
IL-10
(IL10,P22301)
IL-19
(IL19,Q
9U
H
D
0),
IL-20
(IL20,Q
9N
YY1),
IL-24
(IL24,Q
13007)
IL-20
(IL20,Q
9N
YY1),IL-24
(IL24,Q
13007)
IL-22
(IL22,Q
9G
ZX
6)
–
IFN
-λ
1
(IFN
L1,Q
8IU
54),
IFN
-λ
2
(IFN
L2,Q
8IZJ0),
IFN
-λ
3
(IFN
L3,Q
8IZI9)
C
om
m
ents
–
–
–
–
Soluble
decoy
receptor
that
binds
IL-22
(IL22,Q
9G
ZX
6)
as
a
m
onom
er.
–
Subunits
N
om
enclature
Interleukin
10
receptor,α
subunit
Interleukin
10
receptor,β
subunit
Interleukin
20
receptor,α
subunit
Interleukin
20
receptor,β
subunit
Interleukin
22
receptor,
α
1
subunit
Interferon-λ
receptor
subunit
1
H
G
N
C
,U
niProt
IL10RA,Q
13651
IL10RB,Q
08334
IL20RA,Q
9U
H
F4
IL20RB,Q
6U
X
L0
IL22RA1,Q
8N
6P7
IFN
LR1,Q
8IU
57
Fu
rth
er
read
in
g
o
n
IL
-10
recep
to
r
fam
ily
Felix
J
et
al.
(2017)
M
ech
an
ism
s
of
im
m
un
om
odulation
by
m
am
m
alian
an
d
viraldecoy
receptors:
in
sigh
ts
from
structures.
N
at.Rev.Im
m
unol.17
:112-129
[PM
ID
:28028310]
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Im
m
unoglobulin-like
fam
ily
ofIL-1
receptors
C
atalytic
receptors→
C
ytokin
e
receptor
fam
ily→
Im
m
un
oglobulin
-like
fam
ily
of
IL-1
receptors
O
verview
:Th
e
im
m
un
oglobulin
-like
fam
ily
ofIL-1
receptors
are
h
eterodim
eric
receptors
m
ade
up
ofa
cogn
ate
receptor
subun
it
an
d
an
IL-1
receptor
accessory
p
rotein
,IL1RA
P
(Q
9N
PH
3,also
kn
ow
n
as
C
3orf13,IL-1R
A
cP,IL1R
3).Th
ey
are
ch
aracterised
by
extracellular
im
m
un
oglobulin
-like
dom
ain
s
an
d
an
in
tracellular
Toll/In
terleukin
-1R
(TIR
)
dom
ain
.
N
om
enclature
Interleukin-1
receptor,type
I
Interleukin-33
receptor
Interleukin-36
receptor
Interleukin-1
receptor,type
II
Interleukin-18
receptor
Subunits
IL-1
receptor
accessory
protein
(O
ther
subunit),
Interleukin
1
receptor,type
I
(Ligand-binding
subunit)
IL-1
receptor
accessory
protein
(O
ther
subunit),
Interleukin-1
receptor-like
1
(Ligand-binding
subunit)
IL-1
receptor
accessory
protein
(O
ther
subunit),
Interleukin-1
receptor-like
2
(Ligand-binding
subunit)
IL-1
receptor
accessory
protein
(O
ther
subunit),
Interleukin
1
receptor,type
II
(Ligand-binding
subunit)
IL-18
receptor
accessory
protein
(O
ther
subunit),Interleukin-18
1
(Ligand-binding
subunit)
Inhibitors
anakinra
(pK
d
7.8)
[39]
–
–
–
–
Endogenous
agonists
IL-1α
(IL1A,P01583),IL-1β
(IL1B,P01584)
IL-33
(IL33,O
95760)
IL-36α
(IL36A,Q
9U
H
A7),IL-36β
(IL36B,Q
9N
ZH
7),IL-36γ
(IL36G
,Q
9N
ZH
8)
–
IL-18
(IL18,Q
14116),IL-37
(IL37,Q
9N
ZH
6)
Endogenous
antagonists
IL-1
receptor
antagonist
(IL1RN
,
P18510)
–
IL-36
receptor
antagonist
(IL36RN
,Q
9U
BH
0)
–
–
Selective
antagonists
AF12198
[1]
–
–
–
–
C
om
m
ents
–
–
IL-36
receptor
antagonist
(IL36RN
,Q
9U
BH
0)
is
a
highly
selective
antagonist
ofthe
response
to
IL-36γ
(IL36G
,
Q
9N
ZH
8).
D
ecoy
receptor
that
binds
IL-1α
(IL1A,P01583),IL-1β
(IL1B,
P01584)
and
IL-1
receptor
antagonist
(IL1RN
,
P18510).
–
N
om
enclature
Interleukin
1
receptor,type
I
Interleukin
1
receptor,type
II
Interleukin-1
receptor-like
1
Interleukin-1
receptor-like
2
Interleukin-18
1
H
G
N
C
,U
niProt
IL1R1,P14778
IL1R2,P27930
IL1RL1,Q
01638
IL1RL2,Q
9H
B29
IL18R1,Q
13478
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IL-17
receptor
fam
ily
C
atalytic
receptors→
C
ytokin
e
receptor
fam
ily→
IL-17
receptor
fam
ily
O
verview
:Th
e
IL17
cytokin
e
fam
ily
con
sists
of
six
ligan
ds
(IL-17A
-F),w
h
ich
sign
alth
rough
five
receptors
(IL-17R
A
-E).
N
om
enclature
Interleukin-17
receptor
Interleukin-25
receptor
Interleukin-17C
receptor
Subunits
Interleukin
17
receptor
A
(Ligand-binding
subunit),
interleukin
17
receptor
C
(O
ther
subunit)
Interleukin
17
receptor
B
(Ligand-binding
subunit),
Interleukin
17
receptor
A
(O
ther
subunit)
Interleukin
17
receptor
A
(O
ther
subunit),
Interleukin
17
receptor
E
(Ligand-binding
subunit)
Endogenous
agonists
IL-17A
(IL17A,Q
16552),IL-17A/IL-17F
(IL17A
IL17F,
Q
16552
Q
96PD
4),IL-17F
(IL17F,Q
96PD
4)
IL-17B
(IL17B,Q
9U
H
F5),IL-25
(IL25,Q
9H
293)
IL-17C
(IL17C,Q
9P0M
4)
Subunits
N
om
enclature
Interleukin
17
receptor
A
Interleukin
17
receptor
B
interleukin
17
receptor
C
Interleukin-17
receptor
D
Interleukin
17
receptor
E
H
G
N
C
,U
niProt
IL17RA,Q
96F46
IL17RB,Q
9N
RM
6
IL17RC,Q
8N
AC
3
IL17RD
,Q
8N
FM
7
IL17RE,Q
8N
FR9
Antibodies
brodalum
ab
(Binding)
(pK
d
9.2)
[206]
–
–
–
–
C
om
m
ents
–
–
–
The
endogenous
agonist
for
this
receptor
is
unknow
n.
–
Fu
rth
er
read
in
g
o
n
IL
-17
recep
to
r
fam
ily
Berin
ger,
A
et
al.
(2016)
IL-17
in
C
h
ron
ic
In
flam
m
ation
:
From
D
iscovery
to
Targetin
g.
Trends
M
ol
M
ed
22
:230-41
[PM
ID
:26837266]
Lubberts,
E.
(2015)
Th
e
IL-23-IL-17
axis
in
in
flam
m
atory
arth
ritis.
N
at
Rev
Rheum
atol
11
:
415-29
[PM
ID
:25907700]
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G
D
N
F
receptor
fam
ily
C
atalytic
receptors→
G
D
N
F
receptor
fam
ily
O
verview
:
G
D
N
F
fam
ily
receptors
(provision
aln
om
en
clature)
are
extrin
sic
tyrosin
e
kin
ase
receptors.
Ligan
d
bin
din
g
to
th
e
extracellular
dom
ain
of
th
e
glycosylph
osph
atidylin
ositol-lin
ked
cell-surface
receptors
(tabulated
below
)activates
a
tran
sm
em
bran
e
tyrosin
e
kin
ase
en
zym
e,R
ET
(see
R
eceptor
Tyrosin
e
K
in
ases).Th
e
en
dogen
ous
ligan
ds
are
typically
dim
eric,lin
ked
th
rough
disulph
ide
bridges:glial
cell-derived
n
eurotroph
ic
factor
G
D
N
F
(G
D
N
F,P39905)
(211
aa);n
eurturin
(N
RT
N
,Q
99748)
(197
aa);artem
in
(A
RT
N
,Q
5T4W
7)
(237
aa)
an
d
perseph
in
(PSPN
,O
60542)
(PSPN
,156
aa).
N
om
enclature
G
D
N
F
fam
ily
receptorα
1
G
D
N
F
fam
ily
receptorα
2
G
D
N
F
fam
ily
receptorα
3
G
D
N
F
fam
ily
receptorα
4
H
G
N
C
,U
niProt
G
FRA1,P56159
G
FRA2,O
00451
G
FRA3,O
60609
G
FRA4,Q
9G
ZZ7
C
om
m
on
abreviation
G
FRα
1
G
FRα
2
G
FRα
3
G
FRα
4
Potency
order
G
D
N
F
(G
D
N
F,P39905)
>
neurturin
(N
RTN
,Q
99748)
>
artem
in
(ARTN
,Q
5T4W
7)
neurturin
(N
RTN
,Q
99748)
>
G
D
N
F
(G
D
N
F,P39905)
artem
in
(ARTN
,Q
5T4W
7)
persephin
(PSPN
,
O
60542)
Labelled
ligands
[ 125I]G
D
N
F
(rat)
(pK
d
10.2–11.5)
[90,180]
–
–
–
C
o
m
m
en
ts:
In
h
ibitors
of
oth
er
receptor
tyrosin
e
kin
ases,
such
as
sem
axan
ib,
w
h
ich
in
h
ibits
V
EG
F
receptor
fun
ction
,
m
ay
also
in
h
ibit
R
et
fun
ction
[132].
M
utation
s
of
R
ET
an
d
G
D
N
F
gen
es
m
ay
be
in
volved
in
H
irsch
sprun
g’s
disease,w
h
ich
is
ch
aracterized
by
th
e
absen
ce
of
in
tram
uralgan
glion
cells
in
th
e
h
in
dgut,often
resultin
g
in
in
testin
alobstruction
.
Fu
rth
er
read
in
g
o
n
G
D
N
F
recep
to
r
fam
ily
A
llen
SJetal.(2013)G
D
N
F,N
G
F
an
d
BD
N
F
as
th
erapeutic
option
s
for
n
eurodegen
eration
.
Pharm
a-
col.T
her.138
:155-75
[PM
ID
:23348013]
Iban
ez
C
F
et
al.
(2017)
Biology
of
G
D
N
F
an
d
its
receptors
-
R
elevan
ce
for
disorders
of
th
e
cen
tral
n
ervous
system
.
N
eurobiolD
is
97
:80-89
[PM
ID
:26829643]
M
erigh
iA
.(2016)Targetin
g
th
e
glial-derived
n
eurotroph
ic
factor
an
d
related
m
olecules
for
con
trol-
lin
g
n
orm
alan
d
path
ologic
pain
.
ExpertO
pin
T
her
Targets
20
:193-208
[PM
ID
:26863504]
Integrins
C
atalytic
receptors→
In
tegrin
s
O
verview
:
In
tegrin
s
are
un
usual
sign
allin
g
protein
s
th
at
fun
c-
tion
to
sign
al
both
from
th
e
extracellular
en
viron
m
en
t
in
to
th
e
cell,butalso
from
th
e
cytoplasm
to
th
e
extern
alofth
e
cell.Th
e
in
-
tracellular
sign
allin
g
cascades
associated
w
ith
in
tegrin
activation
focus
on
protein
kin
ase
activities,
such
as
focal
adh
esion
kin
ase
an
d
Src.
Based
on
th
is
association
betw
een
extracellular
sign
als
an
d
in
tracellular
protein
kin
ase
activity,
w
e
h
ave
ch
osen
to
in
-
clude
in
tegrin
s
in
th
e
‘C
atalytic
receptors’section
of
th
e
database
un
tilm
ore
strin
gen
t
criteria
from
N
C
-IU
PH
A
R
allow
s
precise
def-
in
ition
of
th
eir
classification
.
In
tegrin
s
are
h
eterodim
eric
en
tities,
com
posed
of
α
an
d
β
sub-
un
its,
each
1TM
protein
s,
w
h
ich
bin
d
com
pon
en
ts
of
th
e
extra-
cellular
m
atrix
or
coun
ter-receptors
expressed
on
oth
er
cells.O
n
e
class
of
in
tegrin
con
tain
s
an
in
serted
dom
ain
(I)
in
its
α
subun
it,
an
d
ifpresen
t
(in
α
1,α
2,α
10,α
11,α
D
,α
E,α
L,α
M
an
d
α
X
),th
is
I
dom
ain
con
tain
s
th
e
ligan
d
bin
din
g
site.
A
llβ
subun
its
possess
a
sim
ilarI-like
dom
ain
,w
h
ich
h
as
th
e
capacity
to
bin
d
ligan
d,often
recogn
isin
g
th
e
R
G
D
m
otif.Th
e
presen
ce
ofan
α
subun
itIdom
ain
precludes
ligan
d
bin
din
g
th
rough
th
e
β
subun
it.In
tegrin
s
provide
a
lin
k
betw
een
ligan
d
an
d
th
e
actin
cytoskeleton
(th
rough
typi-
cally
sh
ort
in
tracellular
dom
ain
s).
In
tegrin
s
bin
d
severaldivalen
t
cation
s,in
cludin
g
a
M
g
2+
ion
in
th
e
I
or
I-like
dom
ain
th
at
is
es-
sen
tialforligan
d
bin
din
g.O
th
ercation
bin
din
g
sites
m
ay
regulate
in
tegrin
activity
or
stabilise
th
e
3D
structure.
In
tegrin
s
regulate
th
e
activity
ofparticular
protein
kin
ases,in
cludin
g
focaladh
esion
kin
ase
an
d
in
tegrin
-lin
ked
kin
ase.C
ellularactivation
regulates
in
-
tegrin
ligan
d
affin
ity
via
in
side-out
sign
allin
g
an
d
ligan
d
bin
din
g
to
in
tegrin
s
can
regulate
cellular
activity
via
outside-in
sign
allin
g.
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N
om
enclature
integrin
α
1β1
integrin
α
2β1
integrin
α
IIbβ3
integrin
α
4β1
Subunits
integrin,beta
1
subunit
(fibronectin
receptor,beta
polypeptide,
antigen
C
D
29
includes
M
D
F2,M
SK12),
integrin,alpha
1
subunit
integrin,beta
1
subunit
(fibronectin
receptor,beta
polypeptide,
antigen
C
D
29
includes
M
D
F2,M
SK12),
integrin,alpha
2
subunit
(C
D
49B,
alpha
2
subunit
ofVLA-2
receptor)
integrin,beta
3
subunit
(platelet
glycoprotein
IIIa,antigen
C
D
61),
integrin,alpha
IIb
subunit
(platelet
glycoprotein
IIb
ofIIb/IIIa
com
plex,antigen
C
D
41)
integrin,beta
1
subunit
(fibronectin
receptor,beta
polypeptide,
antigen
C
D
29
includes
M
D
F2,M
SK12),
integrin,alpha
4
subunit
(antigen
C
D
49D
,alpha
4
subunit
ofVLA-4
receptor)
Ligands
collagen,lam
inin
collagen,lam
inin,throm
bospondin
fibrinogen
(FG
A
FG
B
FG
G
,P02671
P02675
P02679),fibronectin
(FN
1,P02751),
von
W
illebrand
factor
(VW
F,P04275),
vitronectin
(VTN
,P04004),throm
bospondin
fibronectin
(FN
1,P02751),
vascular
celladhesion
protein
1
(VCAM
1,
P19320),osteopontin
(SPP1,P10451),
throm
bospondin
Inhibitors
obtustatin
(pIC
50
9.1)
[118]
TC
I15
(pIC
50
7.9)
[129]
tirofiban
(pIC
50
9.4)
[182],G
4120
(pK
i 8.4)
[125,204],G
R
144053
(pIC
50
7.4)
[40],
eptifibatide
(pIC
50
6.2–6.8)
[160]
BIO
1211
(pIC
50
8.3–9)
[106],TC
S2314
Antibodies
–
–
abcixim
ab
[34]
natalizum
ab
[140]
C
om
m
ents
–
–
–
LD
V-FITC
is
used
as
a
probe
at
this
receptor.
N
om
enclature
integrin
α
4β7
integrin
α
5β1
integrin
α
6β1
integrin
α
10β1
Subunits
integrin,alpha
4
subunit
(antigen
C
D
49D
,alpha
4
subunit
ofVLA-4
receptor),integrin,beta
7
subunit
integrin,beta
1
subunit
(fibronectin
receptor,beta
polypeptide,
antigen
C
D
29
includes
M
D
F2,M
SK12),
integrin,alpha
5
subunit
(fibronectin
receptor,alpha
polypeptide)
integrin,beta
1
subunit
(fibronectin
receptor,beta
polypeptide,
antigen
C
D
29
includes
M
D
F2,M
SK12),
integrin,alpha
6
subunit
integrin,beta
1
subunit
(fibronectin
receptor,beta
polypeptide,
antigen
C
D
29
includes
M
D
F2,M
SK12),
integrin,alpha
10
subunit
Ligands
–
fibronectin
(FN
1,P02751)
lam
inin
collagen
Antibodies
vedolizum
ab
(Antagonist)
(pIC
50
8.3)
[172]
–
–
–
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N
om
enclature
integrin
α
11β1
integrin
α
Eβ7
integrin
α
Lβ2
integrin
α
Vβ3
Subunits
integrin,beta
1
subunit
(fibronectin
receptor,beta
polypeptide,antigen
C
D
29
includes
M
D
F2,M
SK12),
integrin,alpha
11
subunit
integrin,alpha
E
subunit
(antigen
C
D
103,hum
an
m
ucosallym
phocyte
antigen
1;alpha
polypeptide),
integrin,beta
7
subunit
integrin,beta
2
subunit
(com
plem
ent
com
ponent
3
receptor
3
and
4
subunit),
integrin,alpha
L
subunit
(antigen
C
D
11A
(p180),lym
phocyte
function-
associated
antigen
1;alpha
polypeptide)
integrin,beta
3
subunit
(platelet
glycoprotein
IIIa,antigen
C
D
61),
integrin,alpha
V
subunit
Ligands
collagen
E-cadherin
IC
AM
-1
(ICAM
1,P05362),IC
AM
-2
(ICAM
2,
P13598)
vitronectin
(VTN
,P04004),fibronectin
(FN
1,P02751),fibrinogen
(FG
A
FG
B
FG
G
,
P02671
P02675
P02679),osteopontin
(SPP1,P10451),von
W
illebrand
factor
(VW
F,P04275),throm
bospondin,tenascin
Activators
–
–
–
TP508
(pK
d
7.9)
[36]
Inhibitors
–
–
A286982
(pIC
50
7.4–7.5)
[109]
echistatin
(pIC
50
11.7)
[99],P11
(pIC
50
11.6)
[99],cilengitide
(pIC
50
8.5)
[56]
Antibodies
–
–
–
etaracizum
ab
(Binding)
(pK
d
6.3)
[199]
Subunits
N
om
enclature
integrin,alpha
1
subunit
integrin,alpha
2
subunit
(C
D
49B,alpha
2
subunit
ofVLA-2
receptor)
integrin,alpha
IIb
subunit
(platelet
glycoprotein
IIb
ofIIb/IIIa
com
plex,
antigen
C
D
41)
integrin,alpha
3
subunit
(antigen
C
D
49C
,alpha
3
subunit
ofVLA-3
receptor)
integrin,alpha
4
subunit
(antigen
C
D
49D
,alpha
4
subunit
ofVLA-4
receptor)
integrin,alpha
5
subunit
(fibronectin
receptor,
alpha
polypeptide)
H
G
N
C
,U
niProt
ITG
A1,P56199
ITG
A2,P08514
ITG
A2B,P17301
ITG
A3,P26006
ITG
A4,P13612
ITG
A5,P08648
Ligands
–
–
–
peptide
ligand
2
(pIC
50
7.2)
[203]
–
–
Antibodies
–
–
–
–
natalizum
ab
[140]
–
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N
om
enclature
integrin,alpha
6
subunit
integrin,alpha
7
subunit
integrin,alpha
8
subunit
integrin,alpha
9
subunit
integrin,alpha
10
subunit
integrin,alpha
11
subunit
integrin,alpha
D
subunit
H
G
N
C
,U
niProt
ITG
A6,P23229
ITG
A7,Q
13683
ITG
A8,P53708
ITG
A9,Q
13797
ITG
A10,O
75578
ITG
A11,Q
9U
KX
5
ITG
AD
,Q
13349
N
om
enclature
integrin,alpha
E
subunit
(antigen
C
D
103,hum
an
m
ucosallym
phocyte
antigen
1;alpha
polypeptide)
integrin,alpha
L
subunit
(antigen
C
D
11A
(p180),
lym
phocyte
function-
associated
antigen
1;
alpha
polypeptide)
integrin,alpha
M
subunit
(com
plem
ent
com
ponent
3
receptor
3
subunit)
integrin,alpha
V
subunit
integrin,alpha
X
subunit
(com
plem
ent
com
ponent
3
receptor
4
subunit)
H
G
N
C
,U
niProt
ITG
AE,P38570
ITG
AL,P20701
ITG
AM
,P11215
ITG
AV,P06756
ITG
AX,P20702
Antagonists
–
lifitegrast
(Inhibition)
[20,207]
–
–
–
Antibodies
–
efalizum
ab
(Binding)
(pK
d
11.4)
[96]
–
–
–
N
om
enclature
integrin,beta
1
subunit
(fibronectin
receptor,
beta
polypeptide,
antigen
C
D
29
includes
M
D
F2,M
SK12)
integrin,beta
2
subunit
(com
plem
ent
com
ponent
3
receptor
3
and
4
subunit)
integrin,beta
3
subunit(platelet
glycoprotein
IIIa,
antigen
C
D
61)
integrin,beta
4
subunit
integrin,beta
5
subunit
integrin,beta
6
subunit
integrin,beta
7
subunit
integrin,beta
8
subunit
H
G
N
C
,U
niProt
ITG
B1,P05556
ITG
B2,P05107
ITG
B3,P05106
ITG
B4,P16144
ITG
B5,P18084
ITG
B6,P18564
ITG
B7,P26010
ITG
B8,P26012
C
o
m
m
en
ts:In
teg
rin
lig
an
d
s
C
o
llag
en
is
th
e
m
ost
abun
dan
t
protein
in
m
etazoa,
rich
in
glycin
e
an
d
prolin
e
residues,
m
ade
up
of
cross-lin
ked
triple
h
elical
structures,
gen
erated
prim
arily
by
fibroblasts.
Exten
-
sive
post-tran
slation
al
processin
g
is
con
ducted
by
prolyl
an
d
lysyl
h
ydroxylases,
as
w
ell
as
tran
sglutam
in
ases.
O
ver
40
gen
es
for
collagen
-α
subun
its
h
ave
been
iden
tified
in
th
e
h
um
an
gen
om
e.
Th
e
collagen
-bin
din
g
in
tegrin
s
α
1β1,α
2β1,α
10β1
an
d
α
11β1
recogn
ise
a
ran
ge
of
triple-h
elicalpeptide
m
otifs
in
cludin
g
G
FO
G
ER
(O
=
h
ydroxyprolin
e),a
syn
th
etic
peptide
derived
from
th
e
prim
ary
sequen
ce
of
collagen
I
(C
O
L1A
1
(C
O
L1A
1,
P02452))
an
d
collagen
II
(C
O
L2A
1
(C
O
L2A
1,P02458)).
L
am
in
in
is
an
extracellular
glycoprotein
com
posed
ofα
,β
an
d
γ
ch
ain
s,forw
h
ich
five,fouran
d
th
ree
gen
es,respectively,are
iden
-
tified
in
th
e
h
um
an
gen
om
e.
It
bin
ds
to
α
1β1,α
2β1,α
3,β1,α
7β1
an
d
α
6β4
in
tegrin
s10.
fi
b
rin
o
g
en
(F
G
A
F
G
B
F
G
G
,
P
02671
P
02675
P
02679)
is
a
glycosylated
h
exam
er
com
posed
of
tw
o
α
(FG
A
,
P02671),
tw
o
β
(FG
B,
P02675)
an
d
tw
o
γ
(FG
G
,
P02679,)
subun
its,
lin
ked
by
disulph
ide
bridges.
It
is
foun
d
in
plasm
a
an
d
alph
a
gran
ules
of
platelets.
It
form
s
cross-lin
ks
betw
een
activated
platelets
m
e-
diatin
g
aggregation
by
bin
din
g
α
IIbβ3;
proteolysis
by
th
rom
bin
cleaves
sh
ort
peptides
term
ed
fibrin
opeptides
to
gen
erate
fibrin
,
w
h
ich
polym
erises
as
part
of
th
e
blood
coagulation
cascade.
fi
b
ro
n
ectin
(F
N
1,
P
02751)
is
a
disulph
ide-lin
ked
h
om
odim
er
foun
d
as
tw
o
m
ajor
form
s;
a
soluble
dim
eric
form
foun
d
in
th
e
plasm
a
an
d
a
tissue
version
th
at
is
polym
eric,
w
h
ich
is
secreted
in
to
th
e
extracellular
m
atrix
by
fibroblasts.Splice
variation
ofth
e
gen
e
product
(FN
1,P02751)
gen
erates
m
ultiple
isoform
s.
vitro
n
ectin
(V
T
N
,
P
04004)
is
a
serum
glycoprotein
an
d
extra-
cellular
m
atrix
protein
w
h
ich
is
foun
d
eith
er
as
a
m
on
om
er
or,
follow
in
g
proteolysis,a
disulph
ide
-lin
ked
dim
er.
o
steo
p
o
n
tin
(SP
P
1,
P
10451)
form
s
an
in
tegral
part
of
th
e
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database:http://w
w
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m
in
eralized
m
atrix
in
bon
e,
w
h
ere
it
un
dergoes
exten
sive
post-
tran
slation
processin
g,
in
cludin
g
proteolysis
an
d
ph
osph
oryla-
tion
.
vo
n
W
illeb
ran
d
facto
r
(V
W
F
,P
04275)
is
a
glycoprotein
syn
-
th
esised
in
vascular
en
doth
elial
cells
as
a
disulph
ide-lin
ked
h
o-
m
odim
er,but
m
ultim
erises
furth
er
in
plasm
a
an
d
is
deposited
on
vessel
w
all
collagen
as
a
h
igh
m
olecular
w
eigh
t
m
ultim
er.
It
is
respon
sible
for
capturin
g
platelets
un
der
arterial
sh
ear
flow
(via
G
PIb)
an
d
in
th
rom
bus
propagation
(via
in
tegrin
α
IIbβ3).
Fu
rth
er
read
in
g
o
n
In
teg
rin
s
C
lem
etson
,
K
J.
(2017)
Th
e
origin
s
of
m
ajor
platelet
receptor
n
om
en
clature.
Platelets
28
:
40-42
[PM
ID
:27715379]
H
am
idi,H
et
al.
(2016)
Th
e
com
plexity
of
in
tegrin
s
in
can
cer
an
d
n
ew
scopes
for
th
erapeutic
tar-
getin
g.
Br
JC
ancer115
:1017-1023
[PM
ID
:27685444]
H
orton
,
ER
et
al.
(2016)
Th
e
in
tegrin
adh
esom
e
n
etw
ork
at
a
glan
ce.
J
C
ell
Sci
129
:
4159-4163
[PM
ID
:27799358]
Ley,K
etal.(2016)In
tegrin
-based
th
erapeutics:biologicalbasis,clin
icaluse
an
d
n
ew
drugs.N
atRev
D
rug
D
iscov
15
:173-83
[PM
ID
:26822833]
M
an
n
in
en
,
A
et
al.
(2017)
A
proteom
ics
view
on
in
tegrin
-m
ediated
adh
esion
s.
Proteom
ics
17
:
[PM
ID
:27723259]
Park,
Y
K
et
al.
(2016)
In
tegrin
s
in
syn
apse
regulation
.
N
at
Rev
N
eurosci
17
:
745-756
[PM
ID
:27811927]
N
atriuretic
peptide
receptor
fam
ily
C
atalytic
receptors→
N
atriuretic
peptide
receptor
fam
ily
O
verview
:
N
atriuretic
peptide
receptors
(N
PR
s,
provision
al
n
om
en
clature)
are
a
fam
ily
of
h
om
odim
eric,
catalytic
receptors
w
ith
a
sin
gle
TM
dom
ain
an
d
guan
ylylcyclase
(EC
4.6.1.2)
activ-
ity
on
th
e
in
tracellular
dom
ain
of
th
e
protein
sequen
ce.
Isoform
s
are
activated
by
th
e
peptide
h
orm
on
es
atrialn
atriuretic
peptide
(N
PPA
,
P01160),
brain
n
atriuretic
peptide
(N
PPB,
P16860)
an
d
C
-type
n
atriuretic
peptide
(N
PPC
,P23582).A
n
oth
er
fam
ily
m
em
-
ber
is
G
C
-C
,
th
e
receptor
for
guan
ylin
(G
U
C
A
2A
,
Q
02747)
an
d
uroguan
ylin
(G
U
C
A
2B,Q
16661).Fam
ily
m
em
bersh
ave
con
served
ligan
d-bin
din
g,
catalytic
(guan
ylyl
cyclase)
an
d
regulatory
do-
m
ain
s
w
ith
th
e
exception
of
N
PR
-C
w
h
ich
h
as
an
extracellular
bin
din
g
dom
ain
h
om
ologous
to
th
at
of
oth
er
N
PR
s,
but
w
ith
a
trun
cated
in
tracellular
dom
ain
w
h
ich
appears
to
couple,
via
th
e
G
i/o
fam
ily
of
G
protein
s,
to
activation
of
ph
osph
olipase
C
,
in
w
ardly-rectifyin
g
potassium
ch
an
n
els
an
d
in
h
ibition
of
aden
y-
lylcyclase
activity
[136].
N
om
enclature
G
uanylylcyclase-A
G
uanylylcyclase-B
G
uanylylcyclase-C
natriuretic
peptide
receptor
3
H
G
N
C
,U
niProt
N
PR1,P16066
N
PR2,P20594
G
U
CY2C,P25092
N
PR3,P17342
C
om
m
on
abreviation
G
C
-A
G
C
-B
G
C
-C
N
PR-C
Potency
order
atrialnatriuretic
peptide
(N
PPA,P01160)≥
brain
natriuretic
peptide
(N
PPB,P16860)
≫
C
-type
natriuretic
peptide
(N
PPC,
P23582)
[172]
C
-type
natriuretic
peptide
(N
PPC,P23582)
≫
atrialnatriuretic
peptide
(N
PPA,P01160)
≫
brain
natriuretic
peptide
(N
PPB,P16860)
[172]
uroguanylin
(G
U
CA2B,Q
16661)
>
guanylin
(G
U
CA2A,Q
02747)
atrialnatriuretic
peptide
(N
PPA,P01160)
>
C
-type
natriuretic
peptide
(N
PPC,P23582)≥
brain
natriuretic
peptide
(N
PPB,P16860)
[172]
Endogenous
ligands
atrialnatriuretic
peptide
(N
PPA,P01160)
[210]brain
natriuretic
peptide
(N
PPB,
P16860)
[210]
C
-type
natriuretic
peptide
(N
PPC,P23582)
[172]
guanylin
(G
U
CA2A,Q
02747),uroguanylin
(G
U
CA2B,Q
16661)
osteocrin
(O
STN
,P61366)
[148]
Selective
agonists
D
endroaspis
natriuretic
peptide
[211],
sAN
P
[210],cenderitide
[212]
cenderitide
[121],vosoritide
[112]
linaclotide
[18,65],
E.coliheat-stable
enterotoxin
(STa)
[18],
plecanatide
[190]
cAN
F4-23
[132]
Searchable
database:http://w
w
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acology.org/index.jsp
N
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receptor
fam
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(continued)
N
om
enclature
G
uanylylcyclase-A
G
uanylylcyclase-B
G
uanylylcyclase-C
natriuretic
peptide
receptor
3
Selective
antagonists
A-71915
pK
i 9.2–9.5
[213],
[Asu7,23’]β-AN
P-(7-28)
pK
i 7.5
[14],
anantin
[215,216],H
S142-1
[217]
peptide
P19
(pK
d
7.8)
[37],H
S142-1
[151],[Ser11](N
-C
N
P,C
-AN
P)pBN
P2-15
[37],com
pound
C
10
[10]
–
AP811
(pK
i 9.3)
[186],M
372049
[73]
Labelled
ligands
[ 125I]AN
P
(hum
an)
(Agonist)
[ 125I]C
N
P
(hum
an)
[ 125I]Sta
(Agonist)
[63]
[ 125I]AN
P
(hum
an)
C
o
m
m
en
ts:
Th
e
polysacch
aride
obtain
ed
from
ferm
en
tation
of
A
ureobasidium
species,H
S142-1,actsasan
an
tagon
istatboth
G
C
-
A
an
d
G
C
-B
receptors
[133].
G
U
C
Y
2D
(R
etG
C
1,
G
C
-E,
Q
02846)
an
d
G
U
C
Y
2F
(R
etG
C
2,
G
C
-
F,
P51841)
are
predom
in
an
tly
retin
al
guan
ylyl
cyclase
activities,
w
h
ich
are
in
h
ibited
by
calcium
ion
s
actin
g
th
rough
th
e
guan
y-
lyl
cyclase
activatin
g
peptides
G
C
A
P1
(G
U
C
A
1A
,
43080),
G
C
A
P2
(G
U
C
A
1B,Q
9U
M
X
6)
an
d
G
C
A
P3
(G
U
C
A
1C
,O
95843)
[76].
G
C
-D
an
d
G
C
-G
are
pseudogen
es
in
m
an
.
Fu
rth
er
read
in
g
o
n
N
atriu
retic
p
ep
tid
e
recep
to
r
fam
ily
Blom
ain
,
ES
et
al.
(2016)
G
uan
ylyl
C
yclase
C
H
orm
on
e
A
xis
at
th
e
In
tersection
of
O
besity
an
d
C
olorectalC
an
cer.M
olPharm
acol90
:199-204
[PM
ID
:27251363]
K
uh
n
,
M
.(2016)
M
olecular
Ph
ysiology
of
M
em
bran
e
G
uan
ylyl
C
yclase
R
eceptors.
Physiol
Rev
96
:
751-804
[PM
ID
:27030537]
San
th
ekadur,PK
et
al.
(2017)
Th
e
m
ultifaceted
role
of
n
atriuretic
peptides
in
m
etabolic
syn
drom
e.
Biom
ed
Pharm
acother92
:826-835
[PM
ID
:28599248]
Th
eilig,F
etal.(2015)A
N
P-in
duced
sign
alin
g
cascade
an
d
itsim
plication
sin
ren
alpath
oph
ysiology.
A
m
JPhysiolRenalPhysiol308
:F1047-55
[PM
ID
:25651559]
V
olpe,M
etal.(2016)Th
e
n
atriuretic
peptides
system
in
th
e
path
oph
ysiology
ofh
eartfailure:from
m
olecular
basis
to
treatm
en
t.
C
lin
Sci(Lond)130
:57-77
[PM
ID
:26637405]
Pattern
recognition
receptors
C
atalytic
receptors→
Pattern
recogn
ition
receptors
O
verview
:Pattern
R
ecogn
ition
R
eceptors
(PR
R
s,[173])(n
o
m
en
-
clatu
re
as
ag
reed
b
y
N
C
-IU
P
H
A
R
su
b
-co
m
m
ittee
o
n
P
at-
tern
R
eco
g
n
itio
n
R
ecep
to
rs,
[16])
participate
in
th
e
in
n
ate
im
m
un
e
respon
se
to
m
icrobial
agen
ts,
th
e
stim
ulation
of
w
h
ich
leads
to
activation
ofin
tracellularen
zym
es
an
d
regulation
ofgen
e
tran
scription
.PR
R
s
express
m
ultiple
leucin
e-rich
region
s
to
bin
d
a
ran
ge
ofm
icrobially-derived
ligan
ds,term
ed
PA
M
Ps
or
path
ogen
-
associated
m
olecular
pattern
s,
w
h
ich
in
cludes
peptides,
carbo-
h
ydrates,
peptidoglycan
s,
lipoprotein
s,
lipopolysacch
arides,
an
d
n
ucleic
acids.PR
R
s
in
clude
both
cell-surface
an
d
in
tracellularpro-
tein
s.
PR
R
s
m
ay
be
divided
in
to
sign
allin
g-associated
m
em
bers,
iden
tified
h
ere,
an
d
en
docytic
m
em
bers,
th
e
fun
ction
of
w
h
ich
appears
to
be
to
recogn
ise
particular
m
icrobial
m
otifs
for
sub-
sequen
t
cell
attach
m
en
t,
in
tern
alisation
an
d
destruction
.
Som
e
are
in
volved
in
in
flam
m
asom
e
form
ation
,
an
d
m
odulation
IL-1β
cleavage
an
d
secretion
,
an
d
oth
ers
in
th
e
in
itiation
of
th
e
type
I
in
terferon
respon
se.
PR
R
s
in
cluded
in
th
e
G
uide
To
PH
A
R
M
A
C
O
LO
G
Y
are:
C
atalytic
P
R
R
s
(see
lin
ks
below
th
is
overview
)
Toll-like
receptors
(TLR
s)
N
ucleotide-bin
din
g
oligom
erization
dom
ain
-like
receptors
(N
LR
s,
also
kn
ow
n
as
N
O
D
-like
receptors)
R
IG
-I-like
receptors
(R
LR
s)
N
o
n
-catalytic
p
attern
reco
g
n
itio
n
recep
to
rs
A
bsen
t
in
m
elan
om
a
(A
IM
)-like
receptors
(A
LR
s)
C
-type
lectin
-like
receptors
(C
LR
s),an
d
O
th
er
pattern
recogn
ition
receptors.
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Toll-like
receptor
fam
ily
C
atalytic
receptors→
Pattern
recogn
ition
receptors→
Toll-like
receptor
fam
ily
O
verview
:
M
em
bers
of
th
e
toll-like
fam
ily
of
receptors
(n
om
en
-
clature
recom
m
en
ded
by
th
e
N
C
-IU
PH
A
R
subcom
m
ittee
on
pat-
tern
recogn
ition
receptors,[16])
sh
are
sign
ifican
t
h
om
ology
w
ith
th
e
in
terleukin
-1
receptor
fam
ily
an
d
appear
to
require
dim
eriza-
tion
eith
er
as
h
om
o-
or
h
eterodim
ers
for
fun
ction
alactivity.
H
et-
erodim
erization
appears
to
in
fluen
ce
th
e
poten
cy
of
ligan
d
bin
d-
in
g
substan
tially
(e.g.
TLR
1/2
an
d
TLR
2/6,
[174,
175]).
TLR
1,
TLR
2,TLR
4,TLR
5,TLR
6
an
d
TLR
11
are
cell-surface
protein
s,w
h
ile
oth
er
m
em
bers
are
associated
w
ith
in
tracellular
organ
elles,
sig-
n
allin
g
th
rough
th
e
M
yD
88-depen
den
t
path
w
ays
(w
ith
th
e
ex-
ception
of
TLR
3).
A
s
w
ell
as
respon
din
g
to
exogen
ous
in
fectious
agen
ts,it
h
as
been
suggested
th
at
selected
m
em
bers
of
th
e
fam
ily
m
ay
be
activated
by
en
dogen
ous
ligan
ds,such
as
h
sp60
(H
SPD
1,
P10809)
[161].
N
om
enclature
TLR1
TLR2
TLR3
TLR4
TLR5
H
G
N
C
,U
niProt
TLR1,Q
15399
TLR2,O
60603
TLR3,O
15455
TLR4,O
00206
TLR5,O
60602
Agonists
–
com
pound
13
[91],peptidoglycan
[163,205]
poly(I:C
)
[5]
LPS
[150],paclitaxel[85]
–
M
ouse
flagellin
[67]
Selective
antagonists
–
–
–
resatorvid
[78]
–
C
om
m
ents
Functions
as
a
heterodim
er
w
ith
TLR2
in
detection
of
triacylated
lipoproteins.
Activated
by
the
synthetic
analogue
Pam
3C
SK4.
Functions
as
a
heterodim
er
w
ith
either
TLR1
or
TLR6
in
the
detection
oftriacylated
and
diacylated
lipopeptides
respectively.TLR1/2
and
2/6
heterodim
ers
can
be
activated
by
the
synthetic
lipopeptides
Pam
3C
SK4
and
Pam
2C
SK4
respectively.There
is
som
e
debate
in
the
field
as
to
w
hether
or
not
peptidoglycan
is
a
direct
agonist
ofTLR2,or
w
hether
the
early
studies
reporting
this
contained
contam
inating
lipoproteins.
Involved
in
endosom
al
detection
ofdsRN
A;
pro-inflam
m
atory.
eritoran
(E5564)
is
a
lipid
A
analogue,w
hich
has
been
described
as
a
TLR4
antagonist
[79].TLR4
signals
in
conjunction
w
ith
the
co-factor
M
D
-2
(LY96).
Involved
in
the
detection
ofbacterialflagellin;
pro-inflam
m
atory.
N
om
enclature
TLR6
TLR7
TLR8
TLR9
TLR10
TLR11
H
G
N
C
,U
niProt
TLR6,Q
9Y2C
9
TLR7,Q
9N
YK1
TLR8,Q
9N
R97
TLR9,Q
9N
R96
TLR10,Q
9BX
R5
–
Agonists
–
im
iquim
od
[70],
loxoribine
[68],
resiquim
od
[70,83]
resiquim
od
[70,83]
–
–
–
Antagonists
–
hydroxychloroquine
(pIC
50
5.6)
[96]
–
hydroxychloroquine
(pIC
50
7.1)
[96]
–
–
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N
om
enclature
TLR6
TLR7
TLR8
TLR9
TLR10
TLR11
C
om
m
ents
Functions
as
a
heterodim
er
w
ith
TLR2.
Involved
in
the
pro-inflam
m
atory
response
to
diacylated
bacteriallipopeptides.
Activated
by
im
idazoquinoline
derivatives
and
RN
A
oligoribonucleotides.
Involved
in
endosom
al
detection
ofssRN
A;
pro-inflam
m
atory.
Activated
by
im
idazoquinoline
derivatives
and
RN
A
oligoribonucleotides.
Endosom
aldetection
of
ssRN
A;pro-inflam
m
atory.
Toll-like
receptor
9
interacts
w
ith
unm
ethylated
C
pG
dinucleotides
from
bacterialD
N
A
[71].
Activated
by
C
pG
rich
D
N
A
sequences;
pro-inflam
m
atory.
TLR10
is
the
only
pattern-recognition
receptor
w
ithout
know
n
ligand
specificity
and
biologicalfunction.
Evidence
suggests
it
plays
a
m
odulatory
role
w
ith
predom
inantly
inhibitory
(anti-inflam
m
atory)
actions
[145].M
urine
TLR10
has
a
retroviral
insertion
that
m
akes
it
non-functional.
Found
in
m
ouse
Fu
rth
er
read
in
g
o
n
T
o
ll-lik
e
recep
to
r
fam
ily
Bryan
t
C
E
et
al.
(2015)
In
tern
ation
al
U
n
ion
of
Basic
an
d
C
lin
ical
Ph
arm
acology.
X
C
V
I.
Pattern
recogn
ition
receptors
in
h
ealth
an
d
disease.Pharm
acolRev
67
:462-504
[PM
ID
:25829385]
G
oulopoulou
S
etal.(2016)Toll-like
R
eceptors
in
th
e
V
ascularSystem
:Sen
sin
g
th
e
D
an
gers
W
ith
in
.
Pharm
acolRev
68
:142-67
[PM
ID
:26721702]
M
icera
A
etal.
(2016)
Toll-Like
R
eceptors
an
d
Tissue
R
em
odelin
g:
Th
e
Pro/C
on
s
R
ecen
t
Fin
din
gs.
J
C
ellPhysiol231
:531-44
[PM
ID
:26248215]
Zh
an
g
Z
etal.(2017)
Tow
ards
a
structuralun
derstan
din
g
of
n
ucleic
acid-sen
sin
g
Toll-like
receptors
in
th
e
in
n
ate
im
m
un
e
system
.
FEBS
Lett[PM
ID
:28686285]
Zin
n
grebe
J
et
al.
(2017)
TLR
s
G
o
Lin
ear
-
O
n
th
e
U
biquitin
Edge.
Trends
M
ol
M
ed
23
:
296-309
[PM
ID
:28325627]
N
O
D
-like
receptor
fam
ily
C
atalytic
receptors→
Pattern
recogn
ition
receptors→
N
O
D
-like
receptor
fam
ily
O
verview
:
Th
e
n
ucleotide-bin
din
g
oligom
erization
dom
ain
,
leucin
e-rich
repeat
(N
LR
)
fam
ily
of
receptors
(n
om
en
clature
rec-
om
m
en
ded
by
th
e
N
C
-IU
PH
A
R
subcom
m
ittee
on
pattern
recog-
n
ition
receptors
[16])sh
are
a
com
m
on
dom
ain
organ
isation
.Th
is
con
sists
of
an
N
-term
in
al
effector
dom
ain
,
a
cen
tral
n
ucleotide-
bin
din
g
an
d
oligom
erization
dom
ain
(N
O
D
;
also
referred
to
as
a
N
A
C
H
T
dom
ain
),an
d
C
-term
in
alleucin
e-rich
repeats(LR
R
)w
h
ich
h
ave
regulatory
an
d
ligan
d
recogn
ition
fun
ction
s.
Th
e
type
of
ef-
fector
dom
ain
h
as
resulted
in
th
e
division
ofN
LR
fam
ily
m
em
bers
in
to
tw
o
m
ajor
sub-fam
ilies,
N
LR
C
an
d
N
LR
P,
alon
g
w
ith
th
ree
sm
aller
sub-fam
ilies
N
LR
A
,
N
LR
B
an
d
N
LR
X
[177].
N
LR
C
m
em
-
bers
express
an
N
-term
in
al
caspase
recruitm
en
t
dom
ain
(C
A
R
D
)
an
d
N
LR
P
m
em
bers
an
N
-term
in
alPyrin
dom
ain
(PY
D
).
U
pon
activation
th
e
N
LR
C
fam
ily
m
em
bers
N
O
D
1
(N
LR
C
1)
an
d
N
O
D
2
(N
LR
C
2)
recruit
a
serin
e/th
reon
in
e
kin
ase
RIPK
2
(recep-
tor
in
teractin
g
serin
e/th
reon
in
e
kin
ase
2,
O
43353,
also
kn
ow
n
as
C
A
R
D
3,
C
A
R
D
IA
K
,
R
IC
K
,
R
IP2)
leadin
g
to
sign
allin
g
th
rough
N
Fκ
B
an
d
M
A
P
kin
ase.
A
ctivation
of
N
LR
C
4
(previously
kn
ow
n
as
IPA
F)
an
d
m
em
bers
ofth
e
N
LR
P3
fam
ily,in
cludin
g
N
LR
P1
an
d
N
LR
P3,leads
to
form
ation
ofa
large
m
ultiprotein
com
plex
kn
ow
n
as
th
e
in
flam
m
asom
e.
In
addition
to
N
LR
protein
s
oth
er
key
m
em
bers
of
th
e
in
flam
m
asom
e
in
clude
th
e
adaptor
protein
A
SC
(apoptosis-associated
speck-like
protein
con
tain
in
g
a
C
A
R
D
,
also
kn
ow
n
as
PY
C
A
RD
,
C
A
R
D
5,
TM
S1,
Q
9U
LZ3)
an
d
in
flam
m
atory
caspases.
Th
e
in
flam
m
asom
e
activates
th
e
pro-in
flam
m
atory
cy-
tokin
es
IL-1β
(IL1B,P01584)
an
d
IL-18
(IL18,Q
14116)
[16,32].
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N
om
enclature
nucleotide
binding
oligom
erization
dom
ain
containing
1
nucleotide
binding
oligom
erization
dom
ain
containing
2
N
LRC
3
N
LRC
4
N
LRC
5
N
LRX
1
C
IITA
H
G
N
C
,U
niProt
N
O
D
1,Q
9Y239
N
O
D
2,Q
9H
C
29
N
LRC3,Q
7RTR2
N
LRC4,Q
9N
PP4
N
LRC5,Q
86W
I3
N
LRX1,Q
86U
T6
CIITA,P33076
C
om
m
on
abreviation
N
O
D
1
N
O
D
2
–
–
–
–
–
Agonists
m
eso-D
AP
m
uram
yldipeptide
–
–
–
–
–
C
om
m
ents
–
N
O
D
2
has
also
been
reported
to
be
activated
by
ssRN
A
[158]although
this
has
not
been
w
idely
reproduced.
–
N
LRC
4
form
s
an
inflam
m
asom
e
in
conjunction
w
ith
the
N
AIP
proteins
and
responds
to
bacterialflagellin
and
type
IIIsecretion
system
rod
proteins.
–
–
–
N
om
enclature
N
LRP1
N
LRP2
N
LRP3
N
LRP4
N
LRP5
N
LRP6
N
LRP7
H
G
N
C
,U
niProt
N
LRP1,Q
9C
000
N
LRP2,Q
9N
X
02
N
LRP3,Q
96P20
N
LRP4,Q
96M
N
2
N
LRP5,P59047
N
LRP6,P59044
N
LRP7,Q
8W
X
94
Inhibitors
–
–
M
C
C
950
(pIC
50
>
8)
[25]
–
–
–
–
Agonists
m
uram
yldipeptide
–
–
–
–
–
–
C
om
m
ents
N
LRP1
has
3
m
urine
orthologues
w
hich
lack
the
N
-term
inalPyrin
dom
ain.M
urine
N
LRP1b
(EN
SM
U
SG
00000070390)
is
the
best
characterised,
responding
to
Anthrax
LethalToxin.
Along
w
ith
N
LRP7,
N
LRP2
is
the
product
ofa
prim
ate-specific
gene
duplication.
M
ultiple
virus
particles
have
been
show
n
to
act
as
agonists,including
Sendai
and
influenza.N
LRP3
has
been
show
n
to
be
activated
follow
ing
disruption
ofcellular
haem
ostasis
by
a
w
ide-variety
ofexogenous
and
endogenous
m
olecules.The
identity
ofthe
precise
agonist
that
interacts
w
ith
N
LRP3
rem
ains
enigm
atic.
Expanded
in
the
m
ouse
resulting
in
7
orthologues.
–
–
Absent
in
m
ouse.Along
w
ith
N
LRP2
the
product
ofa
prim
ate-specific
gene
duplication.
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N
om
enclature
N
LRP8
N
LRP9
N
LRP10
N
LRP11
N
LRP12
N
LRP13
N
LRP14
H
G
N
C
,U
niProt
N
LRP8,Q
86W
28
N
LRP9,Q
7RTR0
N
LRP10,Q
86W
26
N
LRP11,P59045
N
LRP12,P59046
N
LRP13,Q
86W
25
N
LRP14,
Q
86W
24
C
om
m
ents
Absent
in
m
ouse
This
receptor
has
three
m
urine
orthologues.
–
Absent
in
m
ouse
–
Absent
in
m
ouse
–
C
o
m
m
en
ts:
N
LR
P3
h
as
also
been
reported
to
respon
d
to
h
ost-
derived
products,kn
ow
n
as
dan
ger-associated
m
olecular
pattern
s,
or
D
A
M
Ps,
in
cludin
g
uric
acid
[141],
A
TP,L-glucose,
h
yaluron
an
an
d
am
yloid
β
(A
PP,P05067)
[161].
Loss-of-fun
ction
m
utation
s
of
N
LR
P3
are
associated
w
ith
cold
au-
toin
flam
m
atory
an
d
M
uckle-W
ells
syn
drom
es.
Th
isfam
ily
also
in
cludesN
LR
fam
ily,apoptosis
in
h
ibitory
protein
(N
A
IP,
Q
13075)
w
h
ich
can
be
foun
d
in
th
e
’In
h
ibitors
of
apop-
tosis
(IA
P)
protein
fam
ily’in
th
e
O
th
er
protein
targets
section
of
th
e
G
uide.
Fu
rth
er
read
in
g
o
n
N
O
D
-lik
e
recep
to
r
fam
ily
Bryan
t
C
E
et
al.
(2015)
In
tern
ation
al
U
n
ion
of
Basic
an
d
C
lin
ical
Ph
arm
acology.
X
C
V
I.
Pattern
recogn
ition
receptors
in
h
ealth
an
d
disease.Pharm
acolRev
67
:462-504
[PM
ID
:25829385]
K
on
g
X
et
al.
(2017)
Th
e
fun
ction
of
N
O
D
-like
receptors
in
cen
traln
ervous
system
diseases.
J
N
eu-
rosciRes
95
:1565-1573
[PM
ID
:28029680]
M
otta
V
et
al.
(2015)
N
O
D
-like
receptors:
versatile
cytosolic
sen
tin
els.
Physiol
Rev
95
:
149-78
[PM
ID
:25540141]
Receptor
tyrosine
kinases
(RTKs)
C
atalytic
receptors→
R
eceptor
kin
ases→
TK
:Tyrosin
e
kin
ase→
R
eceptor
tyrosin
e
kin
ases
(R
TK
s)
O
verview
:
R
eceptor
tyrosin
e
kin
ases
(R
TK
s),
a
fam
ily
of
cell-
surface
receptors,w
h
ich
tran
sduce
sign
als
to
polypeptide
an
d
pro-
tein
h
orm
on
es,cytokin
es
an
d
grow
th
factors
are
key
regulators
of
criticalcellularprocesses,such
asproliferation
an
d
differen
tiation
,
cellsurvivalan
d
m
etabolism
,cellm
igration
an
d
cellcycle
con
trol
[11,
57,
184].
In
th
e
h
um
an
gen
om
e,
58
R
TK
s
h
ave
been
iden
ti-
fied,w
h
ich
fallin
to
20
fam
ilies
[100].
A
ll
R
TK
s
display
an
extracellular
ligan
d
bin
din
g
dom
ain
,
a
sin
-
gle
tran
sm
em
bran
e
h
elix,
a
cytoplasm
ic
region
con
tain
in
g
th
e
protein
tyrosin
e
kin
ase
activity
(occasion
ally
split
in
to
tw
o
do-
m
ain
s
by
an
in
sertion
,
term
ed
th
e
kin
ase
in
sertion
),
w
ith
juxta-
m
em
bran
e
an
d
C
-term
in
al
regulatory
region
s.
A
gon
ist
bin
din
g
to
th
e
extracellular
dom
ain
evokes
dim
erization
,
an
d
som
etim
es
oligom
erization
,
of
R
TK
s
(a
sm
all
subset
of
R
TK
s
form
s
m
ulti-
m
ers
even
in
th
e
absen
ce
of
activatin
g
ligan
d).
Th
is
leads
to
autoph
osph
orylation
in
th
e
tyrosin
e
kin
ase
dom
ain
in
a
tran
s
orien
tation
,servin
g
as
a
site
ofassem
bly
ofprotein
com
plexes
an
d
stim
ulation
of
m
ultiple
sign
al
tran
sduction
path
w
ays,
in
cludin
g
ph
osph
olipase
C
-γ,
m
itogen
-activated
protein
kin
ases
an
d
ph
os-
ph
atidylin
ositol3-kin
ase
[184].
R
TK
s
are
of
w
idespread
in
terest
n
ot
on
ly
th
rough
ph
ysiological
fun
ction
s,
but
also
as
drug
targets
in
m
an
y
types
of
can
cer
an
d
oth
er
disease
states.
M
an
y
diseases
result
from
gen
etic
ch
an
ges
or
abn
orm
alities
th
at
eith
er
alter
th
e
activity,abun
dan
ce,cellular
distribution
an
d/orregulation
ofR
TK
s.Th
erefore,drugsth
atm
od-
ify
th
e
dysregulated
fun
ction
s
ofth
ese
R
TK
s
h
ave
been
developed
w
h
ich
fallin
to
tw
o
categories.O
n
e
group
is
often
described
as
‘bi-
ologicals’,w
h
ich
block
th
e
activation
ofR
TK
sdirectly
orby
ch
elat-
in
g
th
e
cogn
ate
ligan
ds,
w
h
ile
th
e
secon
d
are
sm
all
m
olecules
design
ed
to
in
h
ibit
th
e
tyrosin
e
kin
ase
activity
directly.
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Type
IRTKs:ErbB
(epiderm
algrow
th
factor)
receptor
fam
ily
C
atalytic
receptors→
R
eceptor
kin
ases→
TK
:Tyrosin
e
kin
ase→
R
eceptor
tyrosin
e
kin
ases
(R
TK
s)→
Type
I
R
TK
s:ErbB
(epiderm
algrow
th
factor)
receptor
fam
ily
O
verview
:
ErbB
fam
ily
receptors
are
C
lass
I
receptor
tyrosin
e
ki-
n
ases
[57].ER
BB2
(also
kn
ow
n
as
H
ER
-2
or
N
EU
)appears
to
act
as
an
essen
tialpartn
er
for
th
e
oth
er
m
em
bers
of
th
e
fam
ily
w
ith
out
itselfbein
g
activated
by
a
cogn
ate
ligan
d
[58].Ligan
ds
ofth
e
ErbB
fam
ily
of
receptors
are
peptides,m
an
y
of
w
h
ich
are
gen
erated
by
proteolytic
cleavage
of
cell-surface
protein
s.
H
ER
/ErbB
is
th
e
vi-
ral
coun
terpart
to
th
e
receptor
tyrosin
e
kin
ase
EG
FR
.
A
ll
fam
ily
m
em
bers
h
eterodim
erize
w
ith
each
oth
er
to
activate
dow
n
stream
sign
allin
g
path
w
aysan
d
are
aberran
tly
expressed
in
m
an
y
can
cers,
particularly
form
s
of
breast
can
cer
an
d
lun
g
can
cer.
M
utation
s
in
th
e
EG
FR
are
respon
sible
foracquired
resistan
ce
to
tyrosin
e
kin
ase
in
h
ibitor
ch
em
oth
erapeutics.
N
om
enclature
epiderm
algrow
th
factor
receptor
erb-b2
receptor
tyrosine
kinase
2
erb-b2
receptor
tyrosine
kinase
3
erb-b2
receptor
tyrosine
kinase
4
H
G
N
C
,U
niProt
EG
FR,P00533
ERBB2,P04626
ERBB3,P21860
ERBB4,Q
15303
EC
num
ber
2.7.10.1
2.7.10.1
2.7.10.1
2.7.10.1
C
om
m
on
abreviation
EG
FR
H
ER2
H
ER3
H
ER4
Endogenous
ligands
EG
F
(EG
F,P01133),H
B-EG
F
(H
BEG
F,
Q
99075),TG
Fα
(TG
FA,P01135),
am
phiregulin
(AREG
,P15514),betacellulin
(BTC,P35070),epigen
(EPG
N
,Q
6U
W
88),
epiregulin
(EREG
,O
14944)
–
neuregulin-1
(N
RG
1,Q
02297),
neuregulin-2
(N
RG
2,O
14511)
H
B-EG
F
(H
BEG
F,Q
99075),betacellulin
(BTC,
P35070),epiregulin
(EREG
,O
14944),
neuregulin-1
(N
RG
1,Q
02297),neuregulin-2
(N
RG
2,O
14511),neuregulin-3
(N
RG
3,
P56975),neuregulin-4
(N
RG
4,Q
8W
W
G
1)
Inhibitors
canertinib
(pK
d
9.7)
[33],afatinib
(pK
d
9.6)
[33],tesevatinib
(pIC
50
9.5)
[63],
afatinib
(pIC
50
8–9.3)
[36,119],erlotinib
(pK
d
9.2)
[33],gefitinib
(pK
d
9)
[33],
poziotinib
(pIC
50
8.3)
[139],neratinib
(pK
d
8.2)[33],lapatinib
(pK
d
8.1)
[33],
C
P-724714
(pIC
50
7.9)
[60],tesevatinib
(pIC
50
7.8)
[63],BM
S-690514
(pIC
50
7.7)
[117]
–
poziotinib
(pIC
50
7.6)
[139]
Antibodies
necitum
um
ab
(Binding)
(pK
d
9.5)
[128],
cetuxim
ab
(Binding)
(pK
d
9.4)
[66]
pertuzum
ab
(Inhibition)
(pIC
50
>
8)
[100],trastuzum
ab
(Inhibition)
–
–
C
o
m
m
en
ts:[ 125I]EG
F
(h
um
an
)
h
as
been
used
to
labelth
e
ErbB1
EG
F
receptor.Th
e
extracellular
dom
ain
of
ErbB2
can
be
targetted
by
th
e
an
tibodies
trastuzum
ab
an
d
pertuzum
ab
to
in
h
ibit
ErbB
fam
ily
action
.Th
e
in
tracellular
A
TP-bin
din
g
site
of
th
e
tyrosin
e
kin
ase
dom
ain
can
be
in
h
ibited
by
G
W
583340
(7.9–8.0,[50]),gefitin
ib,erlotin
ib
an
d
tyrph
ostin
s
A
G
879
an
d
A
G
1478.
Fu
rth
er
read
in
g
o
n
T
yp
e
I
R
T
K
s:
E
rb
B
(ep
id
erm
al
g
ro
w
th
facto
r)
recep
to
r
fam
ily
K
obayash
iY
etal.(2016)
N
ot
allEG
FR
m
utation
s
in
lun
g
can
cer
are
created
equal:Perspectives
for
in
dividualized
treatm
en
t
strategy.
C
ancer
Sci.[PM
ID
:27323238]
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Type
IIRTKs:Insulin
receptor
fam
ily
C
atalytic
receptors→
R
eceptor
kin
ases→
TK
:Tyrosin
e
kin
ase→
R
eceptor
tyrosin
e
kin
ases
(R
TK
s)→
Type
II
R
TK
s:In
sulin
receptor
fam
ily
O
verview
:
Th
e
circulatin
g
peptide
h
orm
on
es
in
sulin
(IN
S,
P01308)
an
d
th
e
related
in
sulin
-like
grow
th
factors
(IG
F)
activate
C
lass
IIreceptor
tyrosin
e
kin
ases
[57],to
evoke
cellular
respon
ses,
m
ediated
th
rough
m
ultiple
in
tracellular
adaptor
protein
s.
Excep-
tion
ally
am
on
gstth
e
catalytic
receptors,th
e
fun
ction
alreceptorin
th
e
in
sulin
receptor
fam
ily
is
derived
from
a
sin
gle
gen
e
product,
cleaved
post-tran
slation
ally
in
to
tw
o
peptides,w
h
ich
th
en
cross-
lin
k
via
disulph
ide
bridges
to
form
a
h
eterotetram
er.In
triguin
gly,
th
e
en
dogen
ous
peptide
ligan
ds
are
form
ed
in
a
parallel
fash
ion
w
ith
post-tran
slation
alprocessin
g
producin
g
a
h
eterodim
erlin
ked
by
disulph
ide
bridges.
Sign
allin
g
th
rough
th
e
receptors
is
m
e-
diated
th
rough
a
rapid
autoph
osph
orylation
even
t
at
in
tracellu-
lar
tyrosin
e
residues,follow
ed
by
recruitm
en
t
ofm
ultiple
adaptor
protein
s,n
otably
IRS1
(P35568),IRS2
(Q
9Y
4H
2),SH
C
1
(P29353),
G
RB2
(P62993)
an
d
SO
S1
(Q
07889).
Serum
levels
offree
IG
Fs
are
keptlow
by
th
e
action
ofIG
F
bin
din
g
protein
s
(IG
FBP1-5,
P08833,
P18065,
P17936,
P22692,
P24593),
w
h
ich
sequester
th
e
IG
Fs;
overexpression
of
IG
FBPs
m
ay
in
duce
apoptosis,w
h
ile
IG
FBP
levels
are
also
altered
in
som
e
can
cers.
N
om
enclature
Insulin
receptor
Insulin-like
grow
th
factor
Ireceptor
Insulin
receptor-related
receptor
H
G
N
C
,U
niProt
IN
SR,P06213
IG
F1R,P08069
IN
SRR,P14616
EC
num
ber
2.7.10.1
2.7.10.1
2.7.10.1
C
om
m
on
abreviation
InsR
IG
F1R
IRR
Inhibitors
–
BM
S-754807
(pIC
50
8.7)
[198],G
SK-1838705A
(pIC
50
8.7)
[159],G
SK-1838705A
(pK
d
8.1)
[33],PQ
401
(pIC
50
>
6)
[47],AG
1024
(pIC
50
4.7)
[153]
–
Selective
inhibitors
–
N
VP-AEW
541
(pIC
50
9.4)
[49]
–
Endogenous
agonists
insulin
(IN
S,P01308)
insulin-like
grow
th
factor
1
(
IG
F1,P05019),insulin-like
grow
th
factor
2
(IG
F2,P01344)
–
C
o
m
m
en
ts:
Th
ere
is
eviden
ce
for
low
poten
cy
bin
din
g
an
d
ac-
tivation
of
in
sulin
receptors
by
IG
F1.
IG
F2
also
bin
ds
an
d
ac-
tivates
th
e
cation
-in
depen
den
t
m
an
n
ose
6-ph
osph
ate
receptor
(also
kn
ow
n
as
th
e
in
sulin
-like
grow
th
factor
2
receptor;
IG
F2R;
P11717),
w
h
ich
lacks
classical
sign
allin
g
capacity
an
d
appears
to
subserve
a
traffickin
g
role
[115].
IN
SR
R
,w
h
ich
h
as
a
m
uch
m
ore
discrete
localization
,
bein
g
predom
in
an
t
in
th
e
kidn
ey
[93],
cur-
ren
tly
lacks
a
cogn
ate
ligan
d
or
eviden
ce
for
fun
ction
alim
pact.
A
n
tibodies
targettin
g
IG
F1,IG
F2
an
d
th
e
extracellular
portion
of
th
e
IG
F1
receptor
are
in
clin
icaltrials.
PQ
401
in
h
ibits
th
e
in
sulin
-like
grow
th
factor
receptor
[5],
w
h
ile
BM
S-536924
in
h
ibits
both
th
e
in
sulin
receptor
an
d
th
e
in
sulin
-
like
grow
th
factor
receptor
[197].
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Type
IIIRTKs:PD
G
FR,C
SFR,Kit,FLT3
receptor
fam
ily
C
atalytic
receptors→
R
eceptor
kin
ases→
TK
:Tyrosin
e
kin
ase→
R
eceptor
tyrosin
e
kin
ases
(R
TK
s)→
Type
III
R
TK
s:PD
G
FR
,C
SFR
,K
it,FLT3
receptor
fam
ily
O
verview
:
Type
III
R
TK
s
in
clude
PD
G
FR
,C
SF-1R
(Em
s),K
it
an
d
FLT3,w
h
ich
fun
ction
as
h
om
o-
or
h
eterodim
ers.
En
dogen
ous
ligan
ds
of
PD
G
F
receptors
are
h
om
o-
or
h
eterodim
eric:
PD
G
FA
,PD
G
FB,
V
EG
FE
an
d
PD
G
FD
(PD
G
FD
,Q
9G
ZP0)
com
bin
e
as
h
om
o-or
h
eterodim
ers
to
activate
h
om
o-or
h
eterodim
eric
PD
G
F
receptors.SC
F
is
a
dim
eric
ligan
d
for
K
IT.Ligan
ds
for
C
SF1R
are
eith
er
m
on
om
eric
or
dim
eric
glycoprotein
s,w
h
ile
th
e
en
dogen
ous
agon
ist
for
FLT3
is
a
h
om
odim
er.
N
om
enclature
platelet
derived
grow
th
factor
receptor
alpha
platelet
derived
grow
th
factor
receptor
beta
KIT
proto-oncogene
receptor
tyrosine
kinase
H
G
N
C
,U
niProt
PD
G
FRA,P16234
PD
G
FRB,P09619
KIT,P10721
EC
num
ber
2.7.10.1
2.7.10.1
2.7.10.1
C
om
m
on
abreviation
PD
G
FRα
PD
G
FRβ
Kit
Endogenous
ligands
PD
G
F
PD
G
F
–
Inhibitors
PP121
(pIC
50
8.7)
[4],crenolanib
(pK
d
8.7)
[69],
EN
M
D
-2076
(pIC
50
7.2)
[149]
crenolanib
(pK
d
8.5)
[69],SU
-14813
(pIC
50
8.4)
[147],
fam
itinib
(pIC
50
8.4)
[21],sunitinib
(pIC
50
8.2)
[89],
sunitinib
(pK
i 8.1)
[127]
sunitinib
(pK
d
9.4)
[33],fam
itinib
(pIC
50
8.7)
[21],
m
asitinib
(pK
d
8.1)
[33],SU
-14813
(pIC
50
7.8)
[147],
AKN
-028
(pIC
50
7.5)
[42],sorafenib
(pIC
50
7.2)
[196]
Selective
inhibitors
C
P-673451
(pIC
50
8)
[156]
C
P-673451
(pIC
50
9)
[156]
–
Endogenous
agonists
–
–
stem
cellfactor
(KITLG
,P21583)
[183]
N
om
enclature
colony
stim
ulating
factor
1
receptor
fm
s
related
tyrosine
kinase
3
H
G
N
C
,U
niProt
CSF1R,P07333
FLT3,P36888
EC
num
ber
2.7.10.1
2.7.10.1
C
om
m
on
abreviation
C
SFR
FLT3
Endogenous
ligands
G
-C
SF
(CSF3,P09919),G
M
-C
SF
(CSF2,P04141),M
-C
SF
(CSF1,P09603)
Fm
s-related
tyrosine
kinase
3
ligand
(FLT3LG
,P49771)
Inhibitors
JN
J-28312141
(pIC
50
9.2)
[116],Ki-20227
(pK
d
9.1)
[33],Ki-20227
(pIC
50
8.7)
[143],G
W
-2580
(pK
d
8.7)
[33],JN
J-28312141
(pK
d
8.5)
[33]
AC
710
(pK
d
9.3)
[108],linifanib
(pK
d
9.2)
[33],dovitinib
(pK
d
9.2)
[33],crenolanib
(pK
d
9.1)
[69],AST-487
(pK
d
9.1)
[33],EN
M
D
-2076
(pIC
50
8.5)
[149],tandutinib
(pK
d
8.5)
[33]
Selective
inhibitors
G
W
-2580
(pIC
50
7.2)
[27]
G
749
(pIC
50
9.4)
[97]
C
om
m
ents
U
pregulation
ofC
SF1R
expression
is
associated
w
ith
m
igroglialactivation
and
im
m
une
pathology
in
Alzherm
er’s
disease
(AD
)
[67,61].Pharm
acologicalinhibition
ofC
SF1R
w
ith
G
W
-2580
reduces
m
icroglialproliferation
and
prevents
disease
progression
in
a
m
ouse
m
odelofAD
,butthis
does
notcorrelate
w
ith
am
yloid-β
plaque
num
bers
[144].
5’-fluoroindirubinoxim
e
has
been
described
as
a
selective
FLT3
inhibitor
[22].
Searchable
database:http://w
w
w.guidetopharm
acology.org/index.jsp
Type
IIIRTKs:PD
G
FR,C
SFR,Kit,FLT3
receptor
fam
ily
S249
FullC
ontents
ofC
onciseG
uide:http://onlinelibrary.w
iley.com
/doi/10.1111/bph.13876/full
S.P.H.Alexanderetal.The
Concise
Guide
to
PHARM
ACOLOGY
2017/18:Catalytic
receptors.British
JournalofPharm
acology
(2017)174,S225–S271
C
o
m
m
en
ts:
V
arious
sm
allm
olecular
in
h
ibitors
of
type
III
R
TK
s
h
ave
been
described,in
cludin
g
im
atin
ib
an
d
n
ilotin
ib
(targettin
g
PD
G
FR
,K
IT
an
d
C
SF1R
);m
idostaurin
an
d
A
C
220
(quizartin
ib;FLT3),
as
w
ellas
pan
-type
III
R
TK
in
h
ibitors
such
as
sun
itin
ib
an
d
sorafen
ib
[148];5’-fluoroin
dirubin
oxim
e
h
as
been
described
as
a
selective
FLT3
in
h
ibitor
[1].
Type
IV
RTKs:VEG
F
(vascular
endothelialgrow
th
factor)
receptor
fam
ily
C
atalytic
receptors→
R
eceptor
kin
ases→
TK
:Tyrosin
e
kin
ase→
R
eceptor
tyrosin
e
kin
ases
(R
TK
s)→
Type
IV
R
TK
s:V
EG
F
(vascular
en
doth
elialgrow
th
factor)
receptor
fam
ily
O
verview
:
V
EG
F
receptors
are
h
om
o-
an
d
h
eterodim
eric
pro-
tein
s,
w
h
ich
are
ch
aracterized
by
seven
Ig-like
loops
in
th
eir
extracellular
dom
ain
s
an
d
a
split
kin
ase
dom
ain
in
th
e
cyto-
plasm
ic
region
.
Th
ey
are
key
regulators
of
an
giogen
esis
an
d
lym
ph
an
giogen
esis;
as
such
,
th
ey
h
ave
been
th
e
focus
of
drug
discovery
for
con
dition
s
such
as
m
etastatic
can
cer.
Splice
vari-
an
ts
of
V
EG
FR
1
an
d
V
EG
FR
2
gen
erate
trun
cated
protein
s
lim
ited
to
th
e
extracellular
dom
ain
s,
capable
of
h
om
odim
erisation
an
d
bin
din
g
V
EG
F
ligan
ds
as
a
soluble,n
on
-sign
allin
g
en
tity.
Ligan
ds
at
V
EG
F
receptors
are
typically
h
om
odim
eric.
V
EG
FA
(V
EG
FA
,
P15692)
is
able
to
activate
V
EG
FR
1
h
om
odim
ers,
V
EG
FR
1/2
h
et-
erodim
ers
an
d
V
EG
FR
2/3
h
eterodim
ers.
V
EG
FB
(V
EG
FB,P49765)
an
d
placen
talgrow
th
factor
(PG
F,
P49763)
activate
V
EG
FR
1
h
o-
m
odim
ers,
w
h
ile
V
EG
FC
(V
EG
FC
,
P49767)
an
d
V
EG
FD
(V
EG
FD
,
O
43915)
activate
V
EG
FR
2/3
h
eterodim
ers
an
d
V
EG
FR
3
h
om
od-
im
ers,an
d,follow
in
g
proteolysis,V
EG
FR
2
h
om
odim
ers.
N
om
enclature
fm
s
related
tyrosine
kinase
1
kinase
insert
dom
ain
receptor
fm
s
related
tyrosine
kinase
4
H
G
N
C
,U
niProt
FLT1,P17948
KD
R,P35968
FLT4,P35916
EC
num
ber
2.7.10.1
2.7.10.1
2.7.10.1
C
om
m
on
abreviation
VEG
FR-1
VEG
FR-2
VEG
FR-3
Endogenous
ligands
VEG
FA
(VEG
FA,P15692),VEG
FB
(VEG
FB,
P49765)
VEG
FA
(VEG
FA,P15692),VEG
FC
(VEG
FC,P49767),VEG
FE
(PD
G
FC,Q
9N
RA1)
VEG
FC
(VEG
FC,P49767),VEG
FD
(VEG
FD
,O
43915),VEG
FE
(PD
G
FC,
Q
9N
RA1)
Inhibitors
SU
-14813
(pIC
50
8.7)
[147],C
EP-11981
(pIC
50
8.5)
[75],sem
axanib
(pIC
50
8.1)
[12]
axitinib
(pIC
50
9.6)
[98],cabozantinib
(pIC
50
9.5)
[200],foretinib
(pIC
50
8.2–9.1)
[137],cediranib
(pK
d
9)
[33],tesevatinib
(pIC
50
8.8)
[51],SU
-14813
(pK
d
8.6)
[33],
m
otesanib
(pK
d
8.6)
[33],fam
itinib
(pIC
50
8.3)
[21],axitinib
(pK
d
8.2)
[33]
tesevatinib
(pIC
50
8.1)
[51],sunitinib
(pIC
50
8.1)
[86],nintedanib
(pIC
50
7.9)
[72]
Sub/fam
ily-selective
inhibitors
pazopanib
(pIC
50
8)
[66]
pazopanib
(pK
d
7.8)
[33],pazopanib
(pIC
50
7.5)
[79]
pazopanib
(pIC
50
7.3)
[66]
Antibodies
–
ram
ucirum
ab
(Antagonist)
(pIC
50
9)
[113]
–
C
o
m
m
en
ts:
Th
e
V
EG
FR
,
as
w
ell
as
V
EG
F
ligan
ds,
h
ave
been
targeted
by
an
tibodies
an
d
tyrosin
e
kin
ase
in
h
ibitors.
D
M
H
4
[45],
K
i8751
[92]
an
d
ZM
323881,
a
n
ovel
in
h
ibitor
of
vascular
en
doth
elial
grow
th
factor-receptor-2
tyrosin
e
kin
ase
activity
[193]are
described
as
V
EG
FR
2-selective
tyrosin
e
kin
ase
in
h
ibitors.Bevacizum
ab
is
a
m
on
oclon
alan
tibody
directed
again
st
V
EG
F-A
,used
clin
ically
for
th
e
treatm
en
t
of
certain
m
etastatic
can
cers;an
an
tibody
fragm
en
t
h
as
been
used
for
w
et
age-related
m
acular
degen
eration
.
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Type
V
RTKs:FG
F
(fibroblast
grow
th
factor)
receptor
fam
ily
C
atalytic
receptors→
R
eceptor
kin
ases→
TK
:Tyrosin
e
kin
ase→
R
eceptor
tyrosin
e
kin
ases
(R
TK
s)→
Type
V
R
TK
s:FG
F
(fibroblast
grow
th
factor)
receptor
fam
ily
O
verview
:Fibroblast
grow
th
factor
(FG
F)
fam
ily
receptors
act
as
h
om
o-an
d
h
eterodim
ers,an
d
are
ch
aracterized
by
Ig-like
loops
in
th
e
extracellular
dom
ain
,
in
w
h
ich
disulph
ide
bridges
m
ay
form
across
protein
partn
ers
to
allow
th
e
form
ation
of
covalen
t
dim
ers
w
h
ich
m
ay
be
con
stitutively
active.
FG
F
receptors
h
ave
been
im
-
plicated
in
ach
on
droplasia,
an
giogen
esis
an
d
n
um
erous
con
gen
-
ital
disorders.
A
t
least
22
m
em
bers
of
th
e
FG
F
gen
e
fam
ily
h
ave
been
iden
tified
in
th
e
h
um
an
gen
om
e
[8].
W
ith
in
th
is
group,
subfam
ilies
of
FG
F
m
ay
be
divided
in
to
can
on
ical,
in
tracellular
an
d
h
orm
on
e-like
FG
Fs.
FG
F1-FG
F10
h
ave
been
iden
tified
to
act
th
rough
FG
F
receptors,w
h
ile
FG
F11-14
appear
to
sign
al
th
rough
in
tracellular
targets.
O
th
er
fam
ily
m
em
bers
are
less
w
ell
ch
arac-
terized
[192].
N
om
enclature
fibroblast
grow
th
factor
receptor
1
fibroblast
grow
th
factor
receptor
2
fibroblast
grow
th
factor
receptor
3
fibroblast
grow
th
factor
receptor
4
H
G
N
C
,U
niProt
FG
FR1,P11362
FG
FR2,P21802
FG
FR3,P22607
FG
FR4,P22455
EC
num
ber
2.7.10.1
2.7.10.1
2.7.10.1
2.7.10.1
C
om
m
on
abreviation
FG
FR1
FG
FR2
FG
FR3
FG
FR4
Endogenous
ligands
FG
F-1
(FG
F1,P05230),FG
F-2
(FG
F2,P09038),FG
F-4
(FG
F4,
P08620)
>
FG
F-5
(FG
F5,P12034),
FG
F-6
(FG
F6,P10767)
[146]
FG
F-1
(FG
F1,P05230)
>
FG
F-4
(FG
F4,
P08620),FG
F-7
(FG
F7,P21781),FG
F-9
(FG
F9,P31371)
>
FG
F-2
(FG
F2,P09038),
FG
F-6
(FG
F6,P10767)
[146]
FG
F-1
(FG
F1,P05230),FG
F-2
(FG
F2,
P09038),FG
F-9
(FG
F9,P31371)
>
FG
F-4
(FG
F4,P08620),FG
F-8
(FG
F8,
P55075)
[146]
FG
F-1
(FG
F1,P05230),FG
F-2
(FG
F2,P09038),
FG
F-4
(FG
F4,P08620),FG
F-9
(FG
F9,P31371)
>
FG
F-6
(FG
F6,P10767),FG
F-8
(FG
F8,P55075)
[146]
Sub/fam
ily-selective
inhibitors
LY2874455
(pIC
50
8.6)
[205]
LY2874455
(pIC
50
8.6)
[205]
LY2874455
(pIC
50
8.2)
[205]
LY2874455
(pIC
50
8.2)
[205]
Selective
inhibitors
–
–
–
BLU
9931
(pIC
50
8.5)
[75]
Agonists
–
paliferm
in
–
–
C
o
m
m
en
ts:Splice
variation
of
th
e
receptors
can
in
fluen
ce
agon
ist
respon
ses.FG
FRL1
(Q
8N
441)
is
a
trun
cated
kin
ase-n
ullan
alogue.
V
arious
an
tibodies
an
d
tyrosin
e
kin
ase
in
h
ibitors
h
ave
been
developed
again
st
FG
F
receptors
[105,209].PD
161570
is
an
FG
FR
tyrosin
e
kin
ase
in
h
ibitor
[8],w
h
ile
PD
173074
h
as
been
described
to
in
h
ibit
FG
FR
1
an
d
FG
FR
3
[168].
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Type
VIRTKs:PTK7/C
C
K4
C
atalytic
receptors→
R
eceptor
kin
ases→
TK
:Tyrosin
e
kin
ase→
R
eceptor
tyrosin
e
kin
ases
(R
TK
s)→
Type
V
I
R
TK
s:PTK
7/C
C
K
4
O
verview
:
Th
e
PTK
7
receptor
is
associated
w
ith
polarization
of
epith
elial
cells
an
d
th
e
developm
en
t
of
n
eural
structures.
Sequen
ce
an
alysis
suggests
th
at
th
e
gen
e
product
is
catalytically
in
active
as
a
protein
kin
ase,alth
ough
th
ere
is
eviden
ce
for
a
role
in
W
n
t
sign
allin
g
[152].
N
om
enclature
protein
tyrosine
kinase
7
(inactive)
H
G
N
C
,U
niProt
PTK7,Q
13308
EC
num
ber
2.7.10.1
C
om
m
on
abreviation
C
C
K4
C
o
m
m
en
ts:Th
us
far,n
o
selective
PTK
7
in
h
ibitors
h
ave
been
described.
Type
VIIRTKs:N
eurotrophin
receptor/Trk
fam
ily
C
atalytic
receptors→
R
eceptor
kin
ases→
TK
:Tyrosin
e
kin
ase→
R
eceptor
tyrosin
e
kin
ases
(R
TK
s)→
Type
V
II
R
TK
s:N
eurotroph
in
receptor/Trk
fam
ily
O
verview
:
Th
e
n
eurotroph
in
receptor
fam
ily
of
R
TK
s
in
-
clude
trkA
,
trkB
an
d
trkC
(tropom
yosin
-related
kin
ase)
re-
ceptors,
w
h
ich
respon
d
to
N
G
F,
BD
N
F
an
d
n
eurotroph
in
-3,
respectively.
Th
ey
are
associated
prim
arily
w
ith
proliferative
an
d
m
igration
effects
in
n
eural
system
s.
V
arious
isoform
s
of
n
eu-
rotroph
in
receptors
exist,
in
cludin
g
trun
cated
form
s
of
trkB
an
d
trkC
,w
h
ich
lack
catalytic
dom
ain
s.
p75
(TN
FR
SF16,
also
kn
ow
n
as
n
erve
grow
th
factor
receptor),
w
h
ich
h
as
h
om
ologies
w
ith
tum
our
n
ecrosis
factor
receptors,
lacks
a
tyrosin
e
kin
ase
dom
ain
,
but
can
sign
alvia
ceram
ide
release
an
d
n
uclear
factor
κ
B
(N
F-κ
B)
activation
.
Both
trkA
an
d
trkB
con
tain
tw
o
leucin
e-rich
region
s
an
d
can
exist
in
m
on
om
eric
or
dim
eric
form
s.
N
om
enclature
neurotrophic
receptor
tyrosine
kinase
1
neurotrophic
receptor
tyrosine
kinase
2
neurotrophic
receptor
tyrosine
kinase
3
H
G
N
C
,U
niProt
N
TRK1,P04629
N
TRK2,Q
16620
N
TRK3,Q
16288
EC
num
ber
2.7.10.1
2.7.10.1
2.7.10.1
C
om
m
on
abreviation
trkA
trkB
trkC
Endogenous
ligands
N
G
F
(N
G
F,P01138)
>
neurotrophin-3
(N
TF3,
P20783)
BD
N
F
(BD
N
F,P23560),neurotrophin-4
(N
TF4,P34130)
>
neurotrophin-3
(N
TF3,P20783)
neurotrophin-3
(N
TF3,P20783)
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(continued)
N
om
enclature
neurotrophic
receptor
tyrosine
kinase
1
neurotrophic
receptor
tyrosine
kinase
2
neurotrophic
receptor
tyrosine
kinase
3
Inhibitors
com
pound
2c
(pIC
50
8.9)
[189],m
ilciclib
(pIC
50
7.3)
[14]
–
–
Sub/fam
ily-selective
inhibitors
AZD
1332
(pIC
50
>
8.3)
[9],G
N
F-5837
(pIC
50
8)
[2]
AZD
1332
(pIC
50
>
8.3)
[9],G
N
F-5837
(pIC
50
8.1)
[2]
AZD
1332
(pIC
50
>
8.3)
[9],G
N
F-5837
(pIC
50
8.1)
[2]
C
o
m
m
en
ts:
[ 125I]N
G
F
(h
um
an
)
an
d
[ 125I]BD
N
F
(h
um
an
)
h
ave
been
used
to
labelth
e
trkA
an
d
trkB
receptor,respectively.p75
in
-
fluen
ces
th
e
bin
din
g
of
N
G
F
(N
G
F,
P01138)
an
d
n
eurotroph
in
-3
(N
T
F3,
P20783)
to
trkA
.
Th
e
ligan
d
selectivity
of
p75
appears
to
be
depen
den
t
on
th
e
cell
type;
for
exam
ple,in
sym
path
etic
n
eu-
ron
es,
it
bin
ds
n
eurotroph
in
-3
(N
T
F3,
P20783)
w
ith
com
parable
affin
ity
to
trkC
[35].
Sm
all
m
olecule
agon
ists
of
trkB
h
ave
been
described,
in
clud-
in
g
LM
22A
4
[124],
w
h
ile
A
N
A
12
h
as
been
described
as
a
n
on
-
com
petitive
an
tagon
ist
ofBD
N
F
bin
din
g
to
trkB
[20].G
N
F5837
is
a
fam
ily-selective
tyrosin
e
kin
ase
in
h
ibitor
[2],w
h
ile
th
e
tyrosin
e
kin
ase
activity
ofth
e
trkA
receptorcan
be
in
h
ibited
by
G
W
441756
(p
IC
50 =
8.7,[198])
an
d
tyrph
ostin
A
G
879
[162].
Type
VIIIRTKs:RO
R
fam
ily
C
atalytic
receptors→
R
eceptor
kin
ases→
TK
:Tyrosin
e
kin
ase→
R
eceptor
tyrosin
e
kin
ases
(R
TK
s)→
Type
V
III
R
TK
s:R
O
R
fam
ily
O
verview
:M
em
bers
ofth
e
R
O
R
fam
ily
appear
to
be
activated
by
ligan
ds
com
plexin
g
w
ith
oth
er
cell-surface
protein
s.Th
us,R
O
R
1
an
d
R
O
R
2
appear
to
be
activated
by
W
n
t-5a
(W
N
T
5A
,P41221)bin
din
g
to
a
Frizzled
receptor
th
ereby
form
in
g
a
cell-surface
m
ultiprotein
com
plex
[59].
N
om
enclature
receptor
tyrosine
kinase
like
orphan
receptor
1
receptor
tyrosine
kinase
like
orphan
receptor
2
H
G
N
C
,U
niProt
RO
R1,Q
01973
RO
R2,Q
01974
EC
num
ber
2.7.10.1
2.7.10.1
C
om
m
on
abreviation
RO
R1
RO
R2
Searchable
database:http://w
w
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Type
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Type
IX
RTKs:M
uSK
C
atalytic
receptors→
R
eceptor
kin
ases→
TK
:Tyrosin
e
kin
ase→
R
eceptor
tyrosin
e
kin
ases
(R
TK
s)→
Type
IX
R
TK
s:M
uSK
O
verview
:Th
e
m
uscle-specific
kin
ase
M
uSK
is
associated
w
ith
th
e
form
ation
an
d
organ
isation
ofth
e
n
eurom
uscular
jun
ction
from
th
e
skeletalm
uscle
side.A
grin
(A
G
RN
,O
00468)form
s
a
com
plex
w
ith
low
-den
sity
lipoprotein
receptor-related
protein
4
(LRP4,O
75096)
to
activate
M
uSK
[87].
N
om
enclature
m
uscle
associated
receptor
tyrosine
kinase
H
G
N
C
,U
niProt
M
U
SK,O
15146
EC
num
ber
2.7.10.1
C
om
m
on
abreviation
M
uSK
C
o
m
m
en
ts:Th
us
far,n
o
selective
M
uSK
in
h
ibitors
h
ave
been
described.
Type
X
RTKs:H
G
F
(hepatocyte
grow
th
factor)
receptor
fam
ily
C
atalytic
receptors→
R
eceptor
kin
ases→
TK
:Tyrosin
e
kin
ase→
R
eceptor
tyrosin
e
kin
ases
(R
TK
s)→
Type
X
R
TK
s:H
G
F
(h
epatocyte
grow
th
factor)
receptor
fam
ily
O
verview
:H
G
F
receptors
regulate
m
aturation
ofth
e
liverin
th
e
em
bryo,as
w
ellas
h
avin
g
roles
in
th
e
adult,forexam
ple,in
th
e
in
n
ate
im
m
un
e
system
.H
G
F
is
syn
th
esized
as
a
sin
gle
gen
e
product,w
h
ich
is
post-tran
slation
ally
processed
to
yield
a
h
eterodim
er
lin
ked
by
a
disulph
ide
bridge.Th
e
m
aturation
ofH
G
F
is
en
h
an
ced
by
a
serin
e
protease,H
G
F
activatin
g
com
plex,an
d
in
h
ibited
by
H
G
F-in
h
ibitor
1
(SPIN
T
1,O
43278),a
serin
e
protease
in
h
ibitor.M
ST1,th
e
ligan
d
of
R
O
N
,is
tw
o
disulph
ide-lin
ked
peptide
ch
ain
s
gen
erated
by
proteolysis
of
a
sin
gle
gen
e
product.
N
om
enclature
M
ET
proto-oncogene,receptor
tyrosine
kinase
m
acrophage
stim
ulating
1
receptor
H
G
N
C
,U
niProt
M
ET,P08581
M
ST1R,Q
04912
EC
num
ber
2.7.10.1
2.7.10.1
C
om
m
on
abreviation
M
ET
Ron
Endogenous
ligands
hepatocyte
grow
th
factor
(H
G
F,P14210)
m
acrophage
stim
ulating
protein
1
(M
ST1,P09603)
Inhibitors
capm
atinib
(pIC
50
9.9)
[111],SG
X
-523
(pK
d
9.7)
[33],PH
A-665752
(pK
d
9.6)
[33],foretinib
(pIC
50
9.3–9.4)
[104,137],cabozantinib
(pIC
50
8.9)
[200]
BM
S-777607
(pIC
50
8.7)
[162]
Selective
inhibitors
SG
X
-523
(pIC
50
8.4)
[17]
–
C
o
m
m
en
ts:PF04217903
is
a
selective
M
et
tyrosin
e
kin
ase
in
h
ibitor
[29].SU
11274
is
an
in
h
ibitor
of
th
e
H
G
F
receptor
[185],w
ith
th
e
possibility
of
furth
er
targets
[5].
Searchable
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Type
X
IRTKs:TAM
(TYRO
3-,AX
L-and
M
ER-TK)
receptor
fam
ily
C
atalytic
receptors→
R
eceptor
kin
ases→
TK
:Tyrosin
e
kin
ase→
R
eceptor
tyrosin
e
kin
ases
(R
TK
s)→
Type
X
I
R
TK
s:TA
M
(TY
R
O
3-,A
X
L-an
d
M
ER
-TK
)
receptor
fam
ily
O
verview
:M
em
bers
ofth
is
R
TK
fam
ily
represen
ted
a
n
ovelstructuralm
otif,w
h
en
sequen
ced.Th
e
ligan
ds
for
th
is
fam
ily,grow
th
arrest
specific
protein
6
(G
A
S6,Q
14393)an
d
protein
S
(PRO
S1,P07225),
are
secreted
plasm
a
protein
s
w
h
ich
un
dergo
vitam
in
K
-depen
den
t
post-tran
slation
al
m
odification
s
gen
eratin
g
carboxyglutam
ate-rich
dom
ain
s
w
h
ich
are
able
to
bin
d
to
n
egatively-ch
arged
surfaces
of
apoptotic
cells.
N
om
enclature
AX
L
receptor
tyrosine
kinase
TYRO
3
protein
tyrosine
kinase
M
ER
proto-oncogene,
tyrosine
kinase
H
G
N
C
,U
niProt
AXL,P30530
TYRO
3,Q
06418
M
ERTK,Q
12866
EC
num
ber
2.7.10.1
2.7.10.1
2.7.10.1
C
om
m
on
abreviation
Axl
Tyro3
M
er
Endogenous
ligands
grow
th
arrest
specific
protein
6
(G
AS6,Q
14393)
[138],protein
S
(PRO
S1,
P07225)
[171]
grow
th
arrest
specific
protein
6
(G
AS6,Q
14393)
[138],protein
S
(PRO
S1,P07225)
[171]
grow
th
arrest
specific
protein
6
(G
AS6,Q
14393)
[138]
C
o
m
m
en
ts:A
X
L
tyrosin
e
kin
ase
in
h
ibitors
h
ave
been
described
[131].
Type
X
IIRTKs:TIE
fam
ily
ofangiopoietin
receptors
C
atalytic
receptors→
R
eceptor
kin
ases→
TK
:Tyrosin
e
kin
ase→
R
eceptor
tyrosin
e
kin
ases
(R
TK
s)→
Type
X
II
R
TK
s:TIE
fam
ily
of
an
giopoietin
receptors
O
verview
:
Th
e
TIE
fam
ily
w
ere
in
itially
associated
w
ith
form
ation
of
blood
vessels.
En
dogen
ous
ligan
ds
are
an
giopoietin
-1
(A
N
G
PT
1,Q
15389),an
giopoietin
-2
(A
N
G
PT
2,O
15123),an
d
an
giopoietin
-4
(A
N
G
PT
4,Q
9Y
264).A
n
giopoietin
-2
(A
N
G
PT
2,O
15123)
appears
to
act
as
an
en
dogen
ous
an
tagon
ist
of
an
giopoietin
-1
fun
ction
.
N
om
enclature
tyrosine
kinase
w
ith
im
m
unoglobulin
like
and
EG
F
like
dom
ains
1
TEK
receptor
tyrosine
kinase
H
G
N
C
,U
niProt
TIE1,P35590
TEK,Q
02763
EC
num
ber
2.7.10.1
2.7.10.1
C
om
m
on
abreviation
TIE1
TIE2
Endogenous
ligands
–
angiopoietin-1
(AN
G
PT1,Q
15389),angiopoietin-4
(AN
G
PT4,Q
9Y264)
Searchable
database:http://w
w
w.guidetopharm
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Type
X
IIIRTKs:Ephrin
receptor
fam
ily
C
atalytic
receptors→
R
eceptor
kin
ases→
TK
:Tyrosin
e
kin
ase→
R
eceptor
tyrosin
e
kin
ases
(R
TK
s)→
Type
X
III
R
TK
s:Eph
rin
receptor
fam
ily
O
verview
:
Eph
rin
receptors
are
a
fam
ily
of
15
R
TK
s
(th
e
largest
fam
ily
of
R
TK
s)
w
ith
tw
o
iden
tified
subfam
ilies
(Eph
A
an
d
Eph
B),
w
h
ich
h
ave
a
role
in
th
e
regulation
of
n
eu-
ron
al
developm
en
t,
cell
m
igration
,
pattern
in
g
an
d
an
gio-
gen
esis.
Th
eir
ligan
ds
are
m
em
bran
e-associated
protein
s,
th
ough
t
to
be
glycosylph
osph
atidylin
ositol-lin
ked
for
Eph
A
(eph
rin
-A
1
(EFN
A
1,
P20827),
eph
rin
-A
2
(EFN
A
2,
O
43921),
eph
rin
-A
3
(EFN
A
3,
P52797),
eph
rin
-A
4
(EFN
A
4,
P52798)
an
d
eph
rin
-A
5
(EFN
A
5,
P52803))
an
d
1TM
protein
s
for
Eph
rin
B
(EN
SFM
00250000002014:
eph
rin
-B1
(EFN
B1,P98172),eph
rin
-B2
(EFN
B2,P52799)
an
d
eph
rin
-B3
(EFN
B3,Q
15768)),alth
ough
th
e
relation
sh
ip
betw
een
ligan
ds
an
d
receptors
h
as
been
in
com
pletely
defin
ed.
N
om
enclature
EPH
receptor
A1
EPH
receptor
A2
EPH
receptor
A3
EPH
receptor
A4
EPH
receptor
A5
EPH
receptor
A6
EPH
receptor
A7
H
G
N
C
,U
niProt
EPH
A1,P21709
EPH
A2,P29317
EPH
A3,P29320
EPH
A4,P54764
EPH
A5,P54756
EPH
A6,Q
9U
F33
EPH
A7,Q
15375
EC
num
ber
2.7.10.1
2.7.10.1
2.7.10.1
2.7.10.1
2.7.10.1
2.7.10.1
2.7.10.1
C
om
m
on
abreviation
EphA1
EphA2
EphA3
EphA4
EphA5
EphA6
EphA7
N
om
enclature
EPH
receptor
A8
EPH
receptor
A10
EPH
receptor
B1
EPH
receptor
B2
EPH
receptor
B3
EPH
receptor
B4
EPH
receptor
B6
H
G
N
C
,U
niProt
EPH
A8,P29322
EPH
A10,Q
5JZY3
EPH
B1,P54762
EPH
B2,P29323
EPH
B3,P54753
EPH
B4,P54760
EPH
B6,O
15197
EC
num
ber
2.7.10.1
2.7.10.1
2.7.10.1
2.7.10.1
2.7.10.1
2.7.10.1
2.7.10.1
C
om
m
on
abreviation
EphA8
EphA10
EphB1
EphB2
EphB3
EphB4
EphB6
Inhibitors
–
–
com
pound
66
(pIC
50
9)
[95]
–
–
tesevatinib
(pIC
50
8.9)
[51]
–
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Type
X
IV
RTKs:RET
C
atalytic
receptors→
R
eceptor
kin
ases→
TK
:Tyrosin
e
kin
ase→
R
eceptor
tyrosin
e
kin
ases
(R
TK
s)→
Type
X
IV
R
TK
s:R
ET
O
verview
:R
etproto-on
cogen
e
(R
earran
ged
durin
g
tran
sfection
)is
a
tran
sm
em
bran
e
tyrosin
e
kin
ase
en
zym
e
w
h
ich
is
em
ployed
as
a
sign
allin
g
partn
erform
em
bers
ofth
e
G
D
N
F
fam
ily
receptors.Ligan
d-
activated
G
FR
appears
to
recruit
R
et
as
a
dim
er,leadin
g
to
activation
offurth
er
in
tracellular
sign
allin
g
path
w
ays.R
et
appears
to
be
in
volved
in
n
euralcrest
developm
en
t,w
h
ile
m
utation
s
m
ay
be
in
volved
in
m
ultiple
en
docrin
e
n
eoplasia,H
irsch
sprun
g’s
disease,an
d
m
edullary
th
yroid
carcin
om
a.
N
om
enclature
ret
proto-oncogene
H
G
N
C
,U
niProt
RET,P07949
EC
num
ber
2.7.10.1
C
om
m
on
abreviation
Ret
Inhibitors
tam
atinib
(pIC
50
8.3)
[23],vandetanib
(pK
d
7.5)
[33]
C
o
m
m
en
ts:A
n
um
ber
of
tyrosin
e
kin
ase
in
h
ibitors
targetin
g
R
ET
h
ave
been
described
[43].
Type
X
V
RTKs:RYK
C
atalytic
receptors→
R
eceptor
kin
ases→
TK
:Tyrosin
e
kin
ase→
R
eceptor
tyrosin
e
kin
ases
(R
TK
s)→
Type
X
V
R
TK
s:RY
K
O
verview
:
Th
e
‘related
to
tyrosin
e
kin
ase
receptor’(R
yk)
is
structurally
atypical
of
th
e
fam
ily
of
R
TK
s,
particularly
in
th
e
activation
an
d
A
TP-bin
din
g
dom
ain
s.
RY
K
h
as
been
suggested
to
lack
kin
ase
activity
an
d
appears
to
be
in
volved,w
ith
FZD
8,in
th
e
W
n
t
sign
allin
g
system
[152].
N
om
enclature
receptor-like
tyrosine
kinase
H
G
N
C
,U
niProt
RYK,P34925
EC
num
ber
2.7.10.1
C
om
m
on
abreviation
RYK
C
o
m
m
en
ts:Th
us
far,n
o
selective
RY
K
in
h
ibitors
h
ave
been
described.
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Type
X
VIRTKs:D
D
R
(collagen
receptor)
fam
ily
C
atalytic
receptors→
R
eceptor
kin
ases→
TK
:Tyrosin
e
kin
ase→
R
eceptor
tyrosin
e
kin
ases
(R
TK
s)→
Type
X
V
I
R
TK
s:D
D
R
(collagen
receptor)
fam
ily
O
verview
:
D
iscoidin
dom
ain
receptors
1
an
d
2
(D
D
R
1
an
d
D
D
R
2)
are
structurally-related
m
em
bran
e
protein
tyrosin
e
kin
ases
activated
by
collagen
.
C
ollagen
is
probably
th
e
m
ost
abun
dan
t
protein
in
m
an
,w
ith
at
least
29
fam
ilies
ofgen
es
en
codin
g
protein
s,w
h
ich
un
dergo
splice
variation
an
d
post-tran
slation
alprocessin
g,an
d
m
ay
exist
in
m
on
om
eric
or
polym
eric
form
s,producin
g
a
triple-stran
ded,
tw
in
e-like
structure.In
m
an
,prin
cipalfam
ily
m
em
bers
in
clude
C
O
L1A
1
(C
O
L1A
1,P02452),C
O
L2A
1
(C
O
L2A
1,P02458),C
O
L3A
1
(C
O
L3A
1,P02461)
an
d
C
O
L4A
1
(C
O
L4A
1,P02462).
N
om
enclature
discoidin
dom
ain
receptor
tyrosine
kinase
1
discoidin
dom
ain
receptor
tyrosine
kinase
2
H
G
N
C
,U
niProt
D
D
R1,Q
08345
D
D
R2,Q
16832
EC
num
ber
2.7.10.1
2.7.10.1
C
om
m
on
abreviation
D
D
R1
D
D
R2
C
o
m
m
en
ts:Th
e
tyrosin
e
kin
ase
in
h
ibitors
ofD
D
R
,im
atin
ib
an
d
n
ilotin
ib,w
ere
iden
tified
from
proteom
ic
an
alysis
[34].O
th
ercollagen
receptors
in
clude
glycoprotein
V
I(Q
9H
C
N
6),leukocyte-associated
im
m
un
oglobulin
-like
receptor
1
(Q
6G
TX
8),leukocyte-associated
im
m
un
oglobulin
-like
receptor
2
(Q
6ISS4)
an
d
osteoclast-associated
im
m
un
oglobulin
-like
receptor
(Q
8IY
S5).
Type
X
VIIRTKs:RO
S
receptors
C
atalytic
receptors→
R
eceptor
kin
ases→
TK
:Tyrosin
e
kin
ase→
R
eceptor
tyrosin
e
kin
ases
(R
TK
s)→
Type
X
V
II
R
TK
s:R
O
S
receptors
N
om
enclature
c-ros
oncogene
1,receptor
tyrosine
kinase
H
G
N
C
,U
niProt
RO
S1,P08922
EC
num
ber
2.7.10.1
C
om
m
on
abreviation
RO
S
C
o
m
m
en
ts:crizotin
ib
is
a
tyrosin
e
kin
ase
in
h
ibitor,an
ti-can
cer
drug
targetin
g
A
LK
an
d
R
O
S1.
Searchable
database:http://w
w
w.guidetopharm
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Type
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S
receptors
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Type
X
VIIIRTKs:LM
R
fam
ily
C
atalytic
receptors→
R
eceptor
kin
ases→
TK
:Tyrosin
e
kin
ase→
R
eceptor
tyrosin
e
kin
ases
(R
TK
s)→
Type
X
V
III
R
TK
s:LM
R
fam
ily
O
verview
:
Th
e
LM
R
kin
ases
are
un
usual
am
on
gst
th
e
R
TK
s
in
possessin
g
a
sh
ort
extracellular
dom
ain
an
d
exten
ded
in
tracellular
dom
ain
(h
en
ce
th
e
‘Lem
ur’n
am
e
reflectin
g
th
e
lon
g
tail).
A
precise
fun
ction
for
th
ese
receptors
h
as
yet
to
be
defin
ed,
alth
ough
LM
R
1
w
as
iden
tified
as
a
poten
tial
m
arker
of
apoptosis
[48],
givin
g
rise
to
th
e
n
am
e
A
A
TY
K
(A
poptosis-associated
tyrosin
e
kin
ase);
w
h
ile
over-expression
in
duces
differen
tiation
in
n
euroblastom
a
cells
[155].
N
om
enclature
apoptosis
associated
tyrosine
kinase
lem
ur
tyrosine
kinase
2
lem
ur
tyrosine
kinase
3
H
G
N
C
,U
niProt
AATK,Q
6ZM
Q
8
LM
TK2,Q
8IW
U
2
LM
TK3,Q
96Q
04
EC
num
ber
2.7.11.1
2.7.11.1
2.7.11.1
C
om
m
on
abreviation
Lm
r1
Lm
r2
Lm
r3
C
o
m
m
en
ts:A
s
yet
n
o
selective
in
h
ibitors
of
th
e
LM
R
fam
ily
h
ave
been
described.
Type
X
IX
RTKs:Leukocyte
tyrosine
kinase
(LTK)
receptor
fam
ily
C
atalytic
receptors→
R
eceptor
kin
ases→
TK
:Tyrosin
e
kin
ase→
R
eceptor
tyrosin
e
kin
ases
(R
TK
s)→
Type
X
IX
R
TK
s:Leukocyte
tyrosin
e
kin
ase
(LTK
)
receptor
fam
ily
O
verview
:
Th
e
LTK
fam
ily
appear
to
lack
en
dogen
ous
ligan
ds.
LTK
is
subject
to
tissue-specific
splice
variation
,w
h
ich
appears
to
gen
erate
products
in
distin
ct
subcellular
location
s.
A
LK
fusion
s
created
by
gen
e
tran
slocation
s
an
d
rearran
gem
en
ts
are
associated
w
ith
m
an
y
types
of
can
cer,in
cludin
g
large
celllym
ph
om
as,in
flam
m
atory
m
yofibrilastic
tum
ours
an
d
n
on
-sm
allcelllun
g
can
cer
[138].
N
om
enclature
leukocyte
receptor
tyrosine
kinase
ALK
receptor
tyrosine
kinase
H
G
N
C
,U
niProt
LTK,P29376
ALK,Q
9U
M
73
EC
num
ber
2.7.10.1
2.7.10.1
C
om
m
on
abreviation
LTK
ALK
Inhibitors
–
G
SK-1838705A
(pIC
50
9.3)
[159],com
pound
8e
(pIC
50
9.1)
[74],crizotinib
(pIC
50
9)
[30],N
VP-TAE684
(pK
d
9)
[33],com
pound
25b
(pIC
50
8.7)
[53]
Selective
inhibitors
–
ceritinib
(pIC
50
9.7)
[120]
C
om
m
ents
–
crizotinib
appears
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ogen
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–
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m
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en
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(2015)
R
egulators
an
d
effectors
of
bon
e
m
orph
ogen
etic
protein
sign
allin
g
in
th
e
car-
diovascular
system
.JPhysiol593
:2995-3011
[PM
ID
:25952563]
M
acias
M
J
et
al.
(2015)
Structural
determ
in
an
ts
of
Sm
ad
fun
ction
in
TG
F-beta
sign
alin
g.
Trends
Biochem
Sci40
:296-308
[PM
ID
:25935112]
M
orrellN
W
et
al.
(2016)
Targetin
g
BM
P
sign
allin
g
in
cardiovascular
disease
an
d
an
aem
ia.
N
at
Rev
C
ardiol13
:106-20
[PM
ID
:26461965]
N
euzillet
C
et
al.
(2015)
Targetin
g
th
e
TG
Fbeta
path
w
ay
for
can
cer
th
erapy.
Pharm
acol
T
her
147
:
22-31
[PM
ID
:25444759]
van
derK
raan
PM
.(2017)Th
e
ch
an
gin
g
role
ofTG
Fbeta
in
h
ealth
y,agein
g
an
d
osteoarth
ritic
join
ts.
N
atRev
Rheum
atol13
:155-163
[PM
ID
:28148919]
Receptor
tyrosine
phosphatase
(RTP)
fam
ily
C
atalytic
receptors→
R
eceptor
tyrosin
e
ph
osph
atase
(R
TP)
fam
ily
O
verview
:
R
eceptor
tyrosin
e
ph
osph
atases
(R
TP)
are
cell-surface
protein
s
w
ith
a
sin
gle
TM
region
an
d
in
tracellular
ph
osph
otyrosin
e
ph
osph
atase
activity.
M
an
y
fam
ily
m
em
bers
exh
ibit
con
stitutive
activity
in
h
eterologous
expression
,deph
osph
orylatin
g
in
tracellular
targets
such
as
Src
tyrosin
e
kin
ase
(SR
C
)
to
activate
sign
allin
g
cascades.Fam
ily
m
em
bers
bin
d
com
pon
en
ts
ofth
e
extracellular
m
atrix
or
cell-surface
protein
s
in
dicatin
g
a
role
in
in
tercellular
com
m
un
ication
.
N
om
enclature
RTP
Type
A
RTP
Type
B
RTP
Type
C
RTP
Type
D
RTP
Type
E
RTP
Type
F
RTP
Type
G
H
G
N
C
,U
niProt
PTPRA,P18433
PTPRB,P23467
PTPRC,P08575
PTPRD
,P23468
PTPRE,P23469
PTPRF,P10586
PTPRG
,P23470
Putative
endogenous
ligands
–
–
galectin-1
(LG
ALS1,
P09382)
[188]
netrin-G
3
ligand
(LRRC4B,Q
9N
T99)
[94]
–
netrin-G
3
ligand
(LRRC4B,Q
9N
T99)
[94]
contactin-3
(CN
TN
3,
Q
9P232),contactin-4
(CN
TN
4,Q
8IW
V2),
contactin-5
(CN
TN
5,
O
94779),contactin-6
(CN
TN
6,Q
9U
Q
52)
[13]
Searchable
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N
om
enclature
RTP
Type
A
RTP
Type
B
RTP
Type
C
RTP
Type
D
RTP
Type
E
RTP
Type
F
RTP
Type
G
Inhibitors
–
–
–
–
–
illudalic
acid
(pIC
50
5.9)
[107]
com
pound
1
(pK
i 5.6)
[166]
N
om
enclature
RTP
Type
H
RTP
Type
J
RTP
Type
K
RTP
Type
M
RTP
Type
N
RTP
Type
N
2
RTP
Type
O
H
G
N
C
,U
niProt
PTPRH
,Q
9H
D
43
PTPRJ,Q
12913
PTPRK,Q
15262
PTPRM
,P28827
PTPRN
,Q
16849
PTPRN
2,Q
92932
PTPRO
,Q
16827
Putative
endogenous
ligands
–
–
galectin-3
(LG
ALS3,P17931),
galectin-3
binding
protein
(LG
ALS3BP,Q
08380)
[88]
–
–
–
–
N
om
enclature
RTP
Type
Q
RTP
Type
R
RTP
Type
S
RTP
Type
T
RTP
Type
U
RTP
Type
Z1
H
G
N
C
,U
niProt
PTPRQ
,Q
9U
M
Z3
PTPRR,Q
15256
PTPRS,Q
13332
PTPRT,O
14522
PTPRU
,Q
92729
PTPRZ1,P23471
Putative
endogenous
ligands
–
–
chondroitin
sulphate
proteoglycan
3
(N
CAN
,
O
14594),netrin-G
3
ligand
(LRRC4B,Q
9N
T99)
[94,165]
–
–
contactin-1
(CN
TN
1,Q
12860),
pleiotrophin
(PTN
,C
9JR52)
(acts
as
a
negative
regulator)
[13,128]
Fu
rth
er
read
in
g
o
n
R
ecep
to
r
tyro
sin
e
p
h
o
sp
h
atase
(R
T
P
)
fam
ily
H
e
R
etal.(2013)Sm
allm
olecule
toolsforfun
ction
alin
terrogation
ofprotein
tyrosin
e
ph
osph
atases.
FEBS
J.280
:731-50
[PM
ID
:22816879]
Papadim
itriou
E
et
al.
(2016)
Pleiotroph
in
an
d
its
receptor
protein
tyrosin
e
ph
osph
atase
beta/zeta
as
regulators
ofan
giogen
esis
an
d
can
cer.Biochim
Biophys
A
cta
1866
:252-265
[PM
ID
:27693125]
Stan
ford
SM
etal.(2017)Targetin
g
Tyrosin
e
Ph
osph
atases:Tim
e
to
En
d
th
e
Stigm
a.
Trends
Pharm
a-
colSci38
:524-540
[PM
ID
:28412041]
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Tum
our
necrosis
factor
(TN
F)
receptor
fam
ily
C
atalytic
receptors→
Tum
our
n
ecrosis
factor
(TN
F)
receptor
fam
ily
O
verview
:
Th
e
TN
F
receptor
superfam
ily
(TN
FR
SF,
provision
al
n
om
en
clature)
displays
lim
ited
h
om
ology
beyon
d
an
extracellu-
lar
dom
ain
rich
in
cystein
e
residues
an
d
is
activated
by
at
least
18
differen
t
h
um
an
h
om
ologues
of
TN
F
referred
to
as
th
e
TN
F
superfam
ily
(TN
FSF).
Som
e
h
om
ologues
lackin
g
tran
sm
em
bran
e
an
d
cytoplasm
ic
dom
ain
s
fun
ction
as
decoy
receptors
bin
din
g
lig-
an
d
w
ith
out
in
ducin
g
cell
sign
allin
g.
M
an
y
of
th
ese
receptors
an
d
ligan
ds
fun
ction
as
m
ultim
eric
en
tities.
Sign
allin
g
th
rough
th
ese
receptors
is
com
plex
an
d
in
volves
in
teraction
w
ith
cyto-
plasm
ic
adaptor
protein
s
(such
as
TR
A
D
D
an
d
TR
A
F1).
Sev-
eral
of
th
ese
receptors
con
tain
cytoplasm
ic
m
otifs
kn
ow
n
as
‘death
dom
ain
s’,
w
h
ich
upon
activation
serve
to
recruit
death
dom
ain
-
an
d
death
effector
dom
ain
-con
tain
in
g
protein
s
crucial
for
th
e
in
itiation
of
an
apoptotic
respon
se.
A
ddition
al
sign
allin
g
path
w
ays
in
clude
th
e
regulation
of
th
e
n
uclear
factor
κ
B
or
m
itogen
-activated
protein
kin
ase
path
w
ays.Ph
arm
acologicalm
a-
n
ipulation
ofth
ese
receptors
is
m
ain
ly
en
acted
th
rough
ch
elatin
g
th
e
en
dogen
ous
agon
ists
w
ith
h
um
an
ised
m
on
oclon
alan
tibodies
(e.g.In
flixim
ab
oradalim
um
ab)orrecom
bin
an
tfusion
protein
s
of
IgG
an
d
soluble
receptors
(e.g.
etan
ercept).
Som
e
m
utated
form
s
of
TN
F
ligan
ds
are
capable
of
selectin
g
for
differen
t
receptor
sub-
types.
N
om
enclature
tum
or
necrosis
factor
receptor
1
tum
or
necrosis
factor
receptor
2
lym
photoxin
β
receptor
O
X
40
C
D
40
Fas
decoy
receptor
3
System
atic
nom
enclature
TN
FRSF1A
TN
FRSF1B
TN
FRSF3
TN
FRSF4
TN
FRSF5
TN
FRSF6
TN
FRSF6B
H
G
N
C
,U
niProt
TN
FRSF1A,P19438
TN
FRSF1B,P20333
LTBR,P36941
TN
FRSF4,P43489
CD
40,P25942
FAS,P25445
TN
FRSF6B,O
95407
Adaptor
proteins
TRAD
D
TRAF1,TRAF2,TRAF5
TRAF3,TRAF4,TRAF5
TRAF1,TRAF2,TRAF3,TRAF5
TRAF1,TRAF2,
TRAF3,TRAF5,
TRAF6
FAD
D
–
C
om
m
on
abreviation
TN
FR1
TN
FR2
–
–
–
–
–
Endogenous
ligands
lym
photoxin-α
(LTA,
P01374),
tum
our
necrosis
factor
m
em
brane
form
(TN
F,P01375),
tum
our
necrosis
factor
shed
form
(TN
F,P01375)
lym
photoxin-α
(LTA,
P01374),
tum
our
necrosis
factor
m
em
brane
form
(TN
F,P01375)
LIG
H
T
(TN
FSF14,
O
43557),
lym
photoxin
β
2 α
1
heterotrim
er
(LTA
LTB,P01374
Q
06643)
O
X
-40
ligand
(TN
FSF4,P23510)
C
D
40
ligand
(CD
40LG
,P29965)
Fas
ligand
(FASLG
,
P48023)
–
Inhibitors
–
–
–
com
pound
1
(pIC
50
5.9)
[169]
–
–
–
C
om
m
ents
–
–
–
The
O
X
40/O
X
40L
pair
is
involved
in
late
T-cellcostim
ulatory
signaling
and
both
are
transiently
expressed
follow
ing
antigen
recognition,and
blocking
O
X
40/O
X
40L
is
reported
to
preventthe
developm
entofdisease
in
in
vivo
autoim
m
une
and
inflam
m
atory
disease
m
odels
[191]
–
–
D
ecoy
receptor
for
LIG
H
T
(TN
FSF14,
O
43557),TL1A
(TN
FSF15,O
95150)
and
Fas
ligand
(FASLG
,P48023).
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N
om
enclature
C
D
27
C
D
30
4-1BB
death
receptor
4
death
receptor
5
decoy
receptor
1
decoy
receptor
2
System
atic
nom
enclature
TN
FRSF7
TN
FRSF8
TN
FRSF9
TN
FRSF10A
TN
FRSF10B
TN
FRSF10C
TN
FRSF10D
H
G
N
C
,U
niProt
CD
27,P26842
TN
FRSF8,P28908
TN
FRSF9,Q
07011
TN
FRSF10A,O
00220
TN
FRSF10B,O
14763
TN
FRSF10C,O
14798
TN
FRSF10D
,Q
9U
BN
6
Adaptor
proteins
TRAF2,SIVA
TRAF1,TRAF2,
TRAF3,TRAF5
TRAF1,TRAF2,TRAF3
FAD
D
FAD
D
–
–
C
om
m
on
abreviation
–
–
–
D
R4
D
R5
–
–
Endogenous
ligands
C
D
70
(CD
70,
P32970)
C
D
30
ligand
(TN
FSF8,P32971)
4-1BB
ligand
(TN
FSF9,P41273)
TRAIL
(TN
FSF10,
P50591)
–
–
–
Endogenous
agonists
–
–
–
–
TRAIL
(TN
FSF10,P50591)
[208]
–
–
Agonists
–
–
–
SC
-67655
[77]
–
–
–
Antibodies
–
brentuxim
ab
vedotin
(Inhibition)
–
–
tigatuzum
ab
(Agonist)
(pK
d ∼
8.5)
[208]
–
–
C
om
m
ents
–
–
–
–
–
D
ecoy
receptor
for
TRAIL
(TN
FSF10,P50591).
D
ecoy
receptor
for
TRAIL
(TN
FSF10,P50591).
N
om
enclature
receptor
activator
ofN
F-kappa
B
osteoprotegerin
death
receptor
3
TW
EAK
receptor
TAC
I
BAFF
receptor
herpes
virus
entry
m
ediator
System
atic
nom
enclature
TN
FRSF11A
TN
FRSF11B
TN
FRSF25
TN
FRSF12A
TN
FRSF13B
TN
FRSF13C
TN
FRSF14
H
G
N
C
,U
niProt
TN
FRSF11A,Q
9Y6Q
6
TN
FRSF11B,O
00300
TN
FRSF25,Q
93038
TN
FRSF12A,
Q
9N
P84
TN
FRSF13B,O
14836
TN
FRSF13C,
Q
96RJ3
TN
FRSF14,Q
92956
Adaptor
proteins
TRAF1,TRAF2,
TRAF3,TRAF5,TRAF6
–
TRAD
D
TRAF1,TRAF2,
TRAF3
TRAF2,TRAF5,TRAF6
TRAF3
TRAF2,TRAF3,TRAF5
C
om
m
on
abreviation
RAN
K
O
PG
D
R3
–
–
BAFF-R
H
VEM
Endogenous
ligands
RAN
K
ligand
(TN
FSF11,O
14788)
–
TL1A
(TN
FSF15,O
95150)
TW
EAK
(TN
FSF12,
O
43508)
APRIL
(TN
FSF13,
O
75888),BAFF
(TN
FSF13B,Q
9Y275)
BAFF
(TN
FSF13B,
Q
9Y275)
B
and
T
lym
phocyte
attenuator
(BTLA,Q
7Z6A9),
LIG
H
T
(TN
FSF14,O
43557),
lym
photoxin-α
(LTA,P01374)
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N
om
enclature
receptor
activator
ofN
F-kappa
B
osteoprotegerin
death
receptor
3
TW
EAK
receptor
TAC
I
BAFF
receptor
herpes
virus
entry
m
ediator
C
om
m
ents
–
Acts
as
a
decoy
receptor
for
RAN
K
ligand
(TN
FSF11,
O
14788)
and
possibly
for
TRAIL
(TN
FSF10,P50591).
The
only
know
n
TN
FSF
ligand
for
D
R3
is
TN
F-like
protein
1A
(TL1A)
[218].
–
–
–
–
N
om
enclature
nerve
grow
th
factor
receptor
B
cellm
aturation
antigen
glucocorticoid-
induced
TN
F
receptor
toxicity
and
JN
K
inducer
RELT
death
receptor
6
System
atic
nom
enclature
TN
FRSF16
TN
FRSF17
TN
FRSF18
TN
FRSF19
TN
FRSF19L
TN
FRSF21
H
G
N
C
,U
niProt
N
G
FR,P08138
TN
FRSF17,Q
02223
TN
FRSF18,Q
9Y5U
5
TN
FRSF19,Q
9N
S68
RELT,Q
969Z4
TN
FRSF21,O
75509
Adaptor
proteins
TRAF2,TRAF4,TRAF6
TRAF1,TRAF2,TRAF3,
TRAF5,TRAF6
TRAF1,TRAF2,
TRAF3,SIVA
TRAF1,TRAF2,TRAF3,
TRAF5
TRAF1
TRAD
D
C
om
m
on
abreviation
–
BC
M
A
G
ITR
TAJ
–
D
R6
Endogenous
ligands
N
G
F
(N
G
F,P01138)
(pIC
50
6)
[97],BD
N
F
(BD
N
F,P23560),neurotrophin-3
(N
TF3,
P20783),neurotrophin-4
(N
TF4,P34130)
APRIL
(TN
FSF13,
O
75888),BAFF
(TN
FSF13B,Q
9Y275)
TL6
(TN
FSF18,
Q
9U
N
G
2)
lym
photoxin-α
(LTA,
P01374)
–
–
C
om
m
ents
O
ne
ofthe
tw
o
receptor
types
for
the
neurotrophins
(factors
that
stim
ulate
neuronalcellsurvivaland
differentiation).
The
other
fam
ily
ofneurotrophin
receptors
are
the
Trk
fam
ily
ofreceptor
tyrosine
kinases.
–
–
Believed
to
be
essential
during
em
bryonic
developm
ent.
Abundant
in
hem
atologic
tissues.Selective
receptor
for
TN
F
receptor-associated
factor
1
(TRAF1).Activates
the
N
F-κ
B
pathw
ay.
–
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N
om
enclature
TN
FRSF22
TN
FRSF23
ectodysplasin
A2
isoform
receptor
ectodysplasin
1,anhidrotic
receptor
System
atic
nom
enclature
–
–
TN
FRS27
–
H
G
N
C
,U
niProt
–
–
ED
A2R,Q
9H
AV5
ED
AR,Q
9U
N
E0
Adaptor
proteins
–
–
TRAF1,TRAF3,TRAF6
TRAF1,TRAF2,TRAF3
Endogenous
ligands
–
–
ectodysplasin
A2
(ED
A,Q
92838)
[201]
ectodysplasin
A1
(ED
A,Q
92838)
[201]
C
om
m
ents
O
nly
identified
in
m
ouse
to
date.A
potentialdecoy
receptor
for
the
cytotoxic
ligand
TN
FSF10/TRAIL.D
oes
not
contain
a
cytoplasm
ic
death
dom
ain
so
does
not
induce
apoptosis,and
does
not
activate
the
N
F-κ
B
signalling
pathw
ay.
O
nly
identified
in
m
ouse
to
date.A
potentialdecoy
receptor
for
the
cytotoxic
ligand
TN
FSF10/TRAIL.D
oes
not
contain
a
cytoplasm
ic
death
dom
ain
so
does
not
induce
apoptosis,and
does
not
activate
the
N
F-κ
B
signalling
pathw
ay.
Receptor
for
the
ED
A-A2
isoform
of
ectodysplasin
encoded
by
the
anhidrotic
ectoderm
aldysplasia
(ED
A)
gene.
C
ellsurface
receptor
for
ectodysplasin
A
(a
m
orphogen
involved
in
the
developm
ent
of
ectoderm
altissues,including
skin,
hair,nails,teeth,and
sw
eat
glands).
C
o
m
m
en
ts:
TN
FR
SF1A
is
preferen
tially
activated
by
th
e
sh
ed
form
of
TN
F
ligan
d,
w
h
ereas
th
e
m
em
bran
e-boun
d
form
of
TN
F
serves
to
activate
TN
FR
SF1A
an
d
TN
FR
SF1B
equally.
Th
e
n
eurotroph
in
s
n
erve
grow
th
factor
(N
G
F
(N
G
F,
P01138)),
brain
-derived
n
eurotroph
ic
factor
(BD
N
F
(BD
N
F,
P23560)),
n
eurotroph
in
-3
(N
T
F3,
P20783)
(N
TF3)
an
d
n
eurotroph
in
-4
(N
T
F4,
P34130)
(N
TF4)
are
structurally
un
related
to
th
e
TN
F
lig-
an
d
superfam
ily
but
exert
som
e
of
th
eir
action
s
th
rough
th
e
ılow
affin
ity
n
erve
grow
th
factor
receptor 
(N
G
FR
(TN
FR
SF16))
as
w
ell
as
th
rough
th
e
TR
K
fam
ily
of
receptor
tyrosin
e
kin
ases.
Th
e
en
-
dogen
ousligan
dsforED
A
R
an
d
ED
A
2R
are,respectively,th
e
m
em
-
bran
e
(Q
92838[1-391])
an
d
secreted
(Q
92838[160-391])
isoform
s
of
Ectodysplasin
-A
(ED
A
,Q
92838).
Fu
rth
er
read
in
g
o
n
T
u
m
o
u
r
n
ecro
sis
facto
r
(T
N
F)
recep
to
r
fam
ily
Blaser
H
et
al.
(2016)
TN
F
an
d
R
O
S
C
rosstalk
in
In
flam
m
ation
.
Trends
C
ell
Biol
26
:
249-61
[PM
ID
:26791157]
C
roft
M
et
al.
(2017)
Beyon
d
TN
F:
TN
F
superfam
ily
cytokin
es
as
targets
for
th
e
treatm
en
t
of
rh
eum
atic
diseases.
N
atRev
Rheum
atol13
:217-233
[PM
ID
:28275260]
K
alliolias
G
D
et
al.
(2016)
TN
F
biology,
path
ogen
ic
m
ech
an
ism
s
an
d
em
ergin
g
th
erapeutic
strate-
gies.
N
atRev
Rheum
atol12
:49-62
[PM
ID
:26656660]
O
lesen
C
M
etal.
(2016)
M
ech
an
ism
s
beh
in
d
efficacy
of
tum
or
n
ecrosis
factor
in
h
ibitors
in
in
flam
-
m
atory
bow
eldiseases.Pharm
acolT
her159
:110-9
[PM
ID
:26808166]
von
K
arstedtS
etal.(2017)Explorin
g
th
e
TR
A
ILslesstravelled:TR
A
IL
in
can
cerbiology
an
d
th
erapy.
N
atRev
C
ancer17
:352-366
[PM
ID
:28536452]
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